AU2001264116A1 - Amidine derivatives as selective antagonists of NMDA receptors - Google Patents
Amidine derivatives as selective antagonists of NMDA receptorsInfo
- Publication number
- AU2001264116A1 AU2001264116A1 AU2001264116A AU2001264116A AU2001264116A1 AU 2001264116 A1 AU2001264116 A1 AU 2001264116A1 AU 2001264116 A AU2001264116 A AU 2001264116A AU 2001264116 A AU2001264116 A AU 2001264116A AU 2001264116 A1 AU2001264116 A1 AU 2001264116A1
- Authority
- AU
- Australia
- Prior art keywords
- cinnamamidine
- compound
- arh
- formula
- benzyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000005557 antagonist Substances 0.000 title description 14
- 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 title description 11
- 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 title description 7
- 150000001409 amidines Chemical class 0.000 title description 4
- 150000001875 compounds Chemical class 0.000 claims description 103
- GDYXPZCCNRBQNS-VOTSOKGWSA-N (e)-3-phenylprop-2-enimidamide Chemical compound NC(=N)\C=C\C1=CC=CC=C1 GDYXPZCCNRBQNS-VOTSOKGWSA-N 0.000 claims description 74
- 125000000217 alkyl group Chemical group 0.000 claims description 30
- 150000003839 salts Chemical class 0.000 claims description 25
- 238000000034 method Methods 0.000 claims description 24
- 239000000651 prodrug Substances 0.000 claims description 20
- 229940002612 prodrug Drugs 0.000 claims description 20
- 229910052739 hydrogen Inorganic materials 0.000 claims description 18
- 239000001257 hydrogen Substances 0.000 claims description 18
- 125000003545 alkoxy group Chemical group 0.000 claims description 12
- 125000003118 aryl group Chemical group 0.000 claims description 12
- 229910052736 halogen Inorganic materials 0.000 claims description 11
- 150000002367 halogens Chemical class 0.000 claims description 11
- 150000004677 hydrates Chemical class 0.000 claims description 11
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 10
- 238000002360 preparation method Methods 0.000 claims description 9
- 230000008569 process Effects 0.000 claims description 9
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims description 8
- 208000012902 Nervous system disease Diseases 0.000 claims description 7
- 208000025966 Neurological disease Diseases 0.000 claims description 7
- 125000001072 heteroaryl group Chemical group 0.000 claims description 6
- 150000002431 hydrogen Chemical class 0.000 claims description 6
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 6
- 230000000926 neurological effect Effects 0.000 claims description 6
- 239000003937 drug carrier Substances 0.000 claims description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 3
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 claims description 3
- 238000010561 standard procedure Methods 0.000 claims description 3
- 238000002560 therapeutic procedure Methods 0.000 claims description 3
- HTWOYHUSBMQFEF-CMDGGOBGSA-N (e)-n'-(2-methylpropyl)-3-phenylprop-2-enimidamide Chemical compound CC(C)CNC(=N)\C=C\C1=CC=CC=C1 HTWOYHUSBMQFEF-CMDGGOBGSA-N 0.000 claims description 2
- KERNZTSMCWMLJM-VOTSOKGWSA-N (e)-n'-[(3,5-dichlorophenyl)methyl]-3-phenylprop-2-enimidamide Chemical compound ClC1=CC(Cl)=CC(CNC(=N)\C=C\C=2C=CC=CC=2)=C1 KERNZTSMCWMLJM-VOTSOKGWSA-N 0.000 claims description 2
- GDXUKTINMMVSAV-FMIVXFBMSA-N (e)-n'-[(4-methoxyphenyl)methyl]-3-phenylprop-2-enimidamide Chemical compound C1=CC(OC)=CC=C1CNC(=N)\C=C\C1=CC=CC=C1 GDXUKTINMMVSAV-FMIVXFBMSA-N 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 2
- 229910052757 nitrogen Inorganic materials 0.000 claims description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims 2
- ZGZIRBIABQGGNW-BUHFOSPRSA-N (e)-3-phenyl-n'-(3-phenylpropyl)prop-2-enimidamide Chemical compound C=1C=CC=CC=1/C=C/C(=N)NCCCC1=CC=CC=C1 ZGZIRBIABQGGNW-BUHFOSPRSA-N 0.000 claims 1
- UJCDGPUOYHLSKU-VOTSOKGWSA-N (e)-3-phenyl-n'-(pyridin-4-ylmethyl)prop-2-enimidamide Chemical compound C=1C=CC=CC=1/C=C/C(=N)NCC1=CC=NC=C1 UJCDGPUOYHLSKU-VOTSOKGWSA-N 0.000 claims 1
- KDOSGXHIWXEYDY-DHZHZOJOSA-N (e)-3-phenyl-n'-[[4-(trifluoromethyl)phenyl]methyl]prop-2-enimidamide Chemical compound C1=CC(C(F)(F)F)=CC=C1CNC(=N)\C=C\C1=CC=CC=C1 KDOSGXHIWXEYDY-DHZHZOJOSA-N 0.000 claims 1
- QGXQDFUDLKBVNH-CMDGGOBGSA-N (e)-n'-(3-methylbutyl)-3-phenylprop-2-enimidamide Chemical compound CC(C)CCNC(=N)\C=C\C1=CC=CC=C1 QGXQDFUDLKBVNH-CMDGGOBGSA-N 0.000 claims 1
- IWCAMQMPTNFBOA-RMKNXTFCSA-N (e)-n'-[(2,5-dichlorophenyl)methyl]-3-phenylprop-2-enimidamide Chemical compound ClC1=CC=C(Cl)C(CNC(=N)\C=C\C=2C=CC=CC=2)=C1 IWCAMQMPTNFBOA-RMKNXTFCSA-N 0.000 claims 1
- NKDIPRWDNFTLLH-VQHVLOKHSA-N (e)-n'-[(3,4-dichlorophenyl)methyl]-3-phenylprop-2-enimidamide Chemical compound C1=C(Cl)C(Cl)=CC=C1CNC(=N)\C=C\C1=CC=CC=C1 NKDIPRWDNFTLLH-VQHVLOKHSA-N 0.000 claims 1
- OFPPFTXIERVMMB-DHZHZOJOSA-N (e)-n'-[(4-chlorophenyl)methyl]-3-phenylprop-2-enimidamide Chemical compound C1=CC(Cl)=CC=C1CNC(=N)\C=C\C1=CC=CC=C1 OFPPFTXIERVMMB-DHZHZOJOSA-N 0.000 claims 1
- VKVJSHDLGOXUHW-VAWYXSNFSA-N (e)-n'-[(4-methylphenyl)methyl]-3-phenylprop-2-enimidamide Chemical compound C1=CC(C)=CC=C1CNC(=N)\C=C\C1=CC=CC=C1 VKVJSHDLGOXUHW-VAWYXSNFSA-N 0.000 claims 1
- XEJXHQIZSDVPSX-VAWYXSNFSA-N (e)-n'-benzyl-3-cyclohexylprop-2-enimidamide Chemical compound C1CCCCC1/C=C/C(=N)NCC1=CC=CC=C1 XEJXHQIZSDVPSX-VAWYXSNFSA-N 0.000 claims 1
- ZXKBZEHBGBLBJO-VAWYXSNFSA-N (e)-n'-cyclohexyl-3-phenylprop-2-enimidamide Chemical compound C=1C=CC=CC=1/C=C/C(=N)NC1CCCCC1 ZXKBZEHBGBLBJO-VAWYXSNFSA-N 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 125000000649 benzylidene group Chemical group [H]C(=[*])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 84
- -1 hydroxy, hydroxymethyl Chemical group 0.000 description 44
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 39
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 32
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 18
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 15
- 239000000203 mixture Substances 0.000 description 14
- 125000001424 substituent group Chemical group 0.000 description 13
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 12
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 12
- 239000000243 solution Substances 0.000 description 11
- 102100022630 Glutamate receptor ionotropic, NMDA 2B Human genes 0.000 description 10
- 108010038912 Retinoid X Receptors Proteins 0.000 description 10
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- 239000007787 solid Substances 0.000 description 9
- 208000002193 Pain Diseases 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 8
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 8
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 8
- 125000001153 fluoro group Chemical group F* 0.000 description 8
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 description 7
- 238000003556 assay Methods 0.000 description 7
- 102000005962 receptors Human genes 0.000 description 7
- 108020003175 receptors Proteins 0.000 description 7
- 239000002904 solvent Substances 0.000 description 7
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 6
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 6
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 6
- 102000034570 NR1 subfamily Human genes 0.000 description 6
- 108020001305 NR1 subfamily Proteins 0.000 description 6
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 230000014509 gene expression Effects 0.000 description 6
- 229960003998 ifenprodil Drugs 0.000 description 6
- 239000000376 reactant Substances 0.000 description 6
- 208000004454 Hyperalgesia Diseases 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 125000002541 furyl group Chemical group 0.000 description 5
- 239000000543 intermediate Substances 0.000 description 5
- 208000004296 neuralgia Diseases 0.000 description 5
- 208000021722 neuropathic pain Diseases 0.000 description 5
- 238000010992 reflux Methods 0.000 description 5
- 102000014649 NMDA glutamate receptor activity proteins Human genes 0.000 description 4
- 208000018737 Parkinson disease Diseases 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 125000001309 chloro group Chemical group Cl* 0.000 description 4
- 125000004210 cyclohexylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 4
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 4
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 4
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 4
- 125000004344 phenylpropyl group Chemical group 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- 125000006239 protecting group Chemical group 0.000 description 4
- 125000006513 pyridinyl methyl group Chemical group 0.000 description 4
- 239000011541 reaction mixture Substances 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 125000005301 thienylmethyl group Chemical group [H]C1=C([H])C([H])=C(S1)C([H])([H])* 0.000 description 4
- UYNVMODNBIQBMV-UHFFFAOYSA-N 4-[1-hydroxy-2-[4-(phenylmethyl)-1-piperidinyl]propyl]phenol Chemical compound C1CC(CC=2C=CC=CC=2)CCN1C(C)C(O)C1=CC=C(O)C=C1 UYNVMODNBIQBMV-UHFFFAOYSA-N 0.000 description 3
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 239000004471 Glycine Substances 0.000 description 3
- 206010019233 Headaches Diseases 0.000 description 3
- 208000035154 Hyperesthesia Diseases 0.000 description 3
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 3
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 229940127523 NMDA Receptor Antagonists Drugs 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000003502 anti-nociceptive effect Effects 0.000 description 3
- 239000012131 assay buffer Substances 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 239000000679 carrageenan Substances 0.000 description 3
- 229920001525 carrageenan Polymers 0.000 description 3
- 235000010418 carrageenan Nutrition 0.000 description 3
- 229940113118 carrageenan Drugs 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- MDKXBBPLEGPIRI-UHFFFAOYSA-N ethoxyethane;methanol Chemical compound OC.CCOCC MDKXBBPLEGPIRI-UHFFFAOYSA-N 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 125000004005 formimidoyl group Chemical group [H]\N=C(/[H])* 0.000 description 3
- 229930195712 glutamate Natural products 0.000 description 3
- 125000005843 halogen group Chemical group 0.000 description 3
- 231100000869 headache Toxicity 0.000 description 3
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 3
- 229960003299 ketamine Drugs 0.000 description 3
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 3
- 125000001624 naphthyl group Chemical group 0.000 description 3
- 125000000286 phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 3
- 125000004076 pyridyl group Chemical group 0.000 description 3
- 125000000168 pyrrolyl group Chemical group 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 125000001544 thienyl group Chemical group 0.000 description 3
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 3
- KPRZOPQOBJRYSW-UHFFFAOYSA-N 2-(aminomethyl)phenol Chemical compound NCC1=CC=CC=C1O KPRZOPQOBJRYSW-UHFFFAOYSA-N 0.000 description 2
- RUHJZSZTSCSTCC-UHFFFAOYSA-N 2-(bromomethyl)naphthalene Chemical compound C1=CC=CC2=CC(CBr)=CC=C21 RUHJZSZTSCSTCC-UHFFFAOYSA-N 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 2
- 208000019901 Anxiety disease Diseases 0.000 description 2
- 206010003591 Ataxia Diseases 0.000 description 2
- 201000006474 Brain Ischemia Diseases 0.000 description 2
- 206010008120 Cerebral ischaemia Diseases 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 208000004547 Hallucinations Diseases 0.000 description 2
- 208000023105 Huntington disease Diseases 0.000 description 2
- MKXZASYAUGDDCJ-SZMVWBNQSA-N LSM-2525 Chemical compound C1CCC[C@H]2[C@@]3([H])N(C)CC[C@]21C1=CC(OC)=CC=C1C3 MKXZASYAUGDDCJ-SZMVWBNQSA-N 0.000 description 2
- 208000019695 Migraine disease Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
- 208000005392 Spasm Diseases 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- 230000008485 antagonism Effects 0.000 description 2
- 230000036506 anxiety Effects 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 125000001246 bromo group Chemical group Br* 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000012876 carrier material Substances 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 210000001638 cerebellum Anatomy 0.000 description 2
- 206010008118 cerebral infarction Diseases 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 125000004093 cyano group Chemical group *C#N 0.000 description 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 229960001985 dextromethorphan Drugs 0.000 description 2
- 125000004212 difluorophenyl group Chemical group 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 206010015037 epilepsy Diseases 0.000 description 2
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 2
- WYGDMBNWWHHXCE-NERPDURBSA-N ethyl (e)-3-phenylprop-2-enimidate;hydrochloride Chemical compound Cl.CCOC(=N)\C=C\C1=CC=CC=C1 WYGDMBNWWHHXCE-NERPDURBSA-N 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 239000011737 fluorine Substances 0.000 description 2
- 125000001207 fluorophenyl group Chemical group 0.000 description 2
- 239000012458 free base Substances 0.000 description 2
- 125000001041 indolyl group Chemical group 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 206010027599 migraine Diseases 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 125000001425 triazolyl group Chemical group 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- CMIBUZBMZCBCAT-HZPDHXFCSA-N (2r,3r)-2,3-bis[(4-methylbenzoyl)oxy]butanedioic acid Chemical compound C1=CC(C)=CC=C1C(=O)O[C@@H](C(O)=O)[C@H](C(O)=O)OC(=O)C1=CC=C(C)C=C1 CMIBUZBMZCBCAT-HZPDHXFCSA-N 0.000 description 1
- LQLOGZQVKUNBRX-UHFFFAOYSA-N (3-iodophenyl)methanamine Chemical compound NCC1=CC=CC(I)=C1 LQLOGZQVKUNBRX-UHFFFAOYSA-N 0.000 description 1
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 description 1
- VFQREFSSUZWIPT-GEEYTBSJSA-N (e)-3-phenyl-n'-[(2-phenylphenyl)methyl]prop-2-enimidamide;hydrochloride Chemical compound Cl.C=1C=CC=CC=1/C=C/C(=N)NCC1=CC=CC=C1C1=CC=CC=C1 VFQREFSSUZWIPT-GEEYTBSJSA-N 0.000 description 1
- HMFLICFUFAXQDQ-ZHACJKMWSA-N (e)-3-phenyl-n'-[[2-(trifluoromethoxy)phenyl]methyl]prop-2-enimidamide Chemical compound FC(F)(F)OC1=CC=CC=C1CNC(=N)\C=C\C1=CC=CC=C1 HMFLICFUFAXQDQ-ZHACJKMWSA-N 0.000 description 1
- QENHDVWRWPITTM-MDZDMXLPSA-N (e)-3-phenyl-n'-[[3-(trifluoromethyl)phenyl]methyl]prop-2-enimidamide Chemical compound FC(F)(F)C1=CC=CC(CNC(=N)\C=C\C=2C=CC=CC=2)=C1 QENHDVWRWPITTM-MDZDMXLPSA-N 0.000 description 1
- ZJYIEIXAMGFZRL-CALJPSDSSA-N (e)-n',3-diphenylprop-2-enimidamide;hydrochloride Chemical compound Cl.C=1C=CC=CC=1/C=C/C(=N)NC1=CC=CC=C1 ZJYIEIXAMGFZRL-CALJPSDSSA-N 0.000 description 1
- NJOJLSWUQNMZBT-MDZDMXLPSA-N (e)-n'-[(2,3-dichlorophenyl)methyl]-3-phenylprop-2-enimidamide Chemical compound ClC1=CC=CC(CNC(=N)\C=C\C=2C=CC=CC=2)=C1Cl NJOJLSWUQNMZBT-MDZDMXLPSA-N 0.000 description 1
- MWQMVEDKVRDZPQ-RRABGKBLSA-N (e)-n'-[(2,3-dichlorophenyl)methyl]-3-phenylprop-2-enimidamide;hydrochloride Chemical compound Cl.ClC1=CC=CC(CNC(=N)\C=C\C=2C=CC=CC=2)=C1Cl MWQMVEDKVRDZPQ-RRABGKBLSA-N 0.000 description 1
- CQSDLAWPJXJUIO-MLBSPLJJSA-N (e)-n'-[(2,5-dichlorophenyl)methyl]-3-phenylprop-2-enimidamide;hydrochloride Chemical compound Cl.ClC1=CC=C(Cl)C(CNC(=N)\C=C\C=2C=CC=CC=2)=C1 CQSDLAWPJXJUIO-MLBSPLJJSA-N 0.000 description 1
- LVCOYKCLVWKECE-ZHACJKMWSA-N (e)-n'-[(2-bromophenyl)methyl]-3-phenylprop-2-enimidamide Chemical compound BrC1=CC=CC=C1CNC(=N)\C=C\C1=CC=CC=C1 LVCOYKCLVWKECE-ZHACJKMWSA-N 0.000 description 1
- DJARJNRIGPBHMR-ZHACJKMWSA-N (e)-n'-[(2-hydroxyphenyl)methyl]-3-phenylprop-2-enimidamide Chemical compound OC1=CC=CC=C1CNC(=N)\C=C\C1=CC=CC=C1 DJARJNRIGPBHMR-ZHACJKMWSA-N 0.000 description 1
- DMXGMEQLKHBQFY-CALJPSDSSA-N (e)-n'-[(4-methylphenyl)methyl]-3-phenylprop-2-enimidamide;hydrochloride Chemical compound Cl.C1=CC(C)=CC=C1CNC(=N)\C=C\C1=CC=CC=C1 DMXGMEQLKHBQFY-CALJPSDSSA-N 0.000 description 1
- JWJXZKMRFMJONH-BXTVWIJMSA-N (e)-n'-benzyl-3-(3,4-difluorophenyl)prop-2-enimidamide;hydrochloride Chemical compound Cl.C1=C(F)C(F)=CC=C1\C=C\C(=N)NCC1=CC=CC=C1 JWJXZKMRFMJONH-BXTVWIJMSA-N 0.000 description 1
- ZAUMCWHDNZJVKX-MDZDMXLPSA-N (e)-n'-benzyl-3-(3-chlorophenyl)prop-2-enimidamide Chemical compound ClC1=CC=CC(\C=C\C(=N)NCC=2C=CC=CC=2)=C1 ZAUMCWHDNZJVKX-MDZDMXLPSA-N 0.000 description 1
- HEXBAJSBFNYKJO-VAWYXSNFSA-N (e)-n'-benzyl-3-phenylprop-2-enimidamide Chemical compound C=1C=CC=CC=1/C=C/C(=N)NCC1=CC=CC=C1 HEXBAJSBFNYKJO-VAWYXSNFSA-N 0.000 description 1
- ZTWPMZJQRDJFBM-KHPPLWFESA-N (z)-n'-benzyl-3-(2-chlorophenyl)prop-2-enimidamide Chemical compound C=1C=CC=CC=1CN=C(N)\C=C/C1=CC=CC=C1Cl ZTWPMZJQRDJFBM-KHPPLWFESA-N 0.000 description 1
- ZJKPLDWGUGMCSW-QXMHVHEDSA-N (z)-n'-benzyl-3-(2-methoxyphenyl)prop-2-enimidamide Chemical compound COC1=CC=CC=C1\C=C/C(N)=NCC1=CC=CC=C1 ZJKPLDWGUGMCSW-QXMHVHEDSA-N 0.000 description 1
- GGUSQTSTQSHJAH-UHFFFAOYSA-N 1-(4-chlorophenyl)-2-[4-(4-fluorobenzyl)piperidin-1-yl]ethanol Chemical compound C=1C=C(Cl)C=CC=1C(O)CN(CC1)CCC1CC1=CC=C(F)C=C1 GGUSQTSTQSHJAH-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- FPYUJUBAXZAQNL-UHFFFAOYSA-N 2-chlorobenzaldehyde Chemical compound ClC1=CC=CC=C1C=O FPYUJUBAXZAQNL-UHFFFAOYSA-N 0.000 description 1
- YTPHFFRQTRUHMW-UHFFFAOYSA-N 2-diethoxyphosphorylethanethioamide Chemical compound CCOP(=O)(CC(N)=S)OCC YTPHFFRQTRUHMW-UHFFFAOYSA-N 0.000 description 1
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- HIJXCSPSAVIBMJ-UHFFFAOYSA-N 3-phenylprop-2-enethioamide Chemical compound NC(=S)C=CC1=CC=CC=C1 HIJXCSPSAVIBMJ-UHFFFAOYSA-N 0.000 description 1
- FTIRTJVRBRTVKN-UHFFFAOYSA-N 3-phenylprop-2-enimidamide;hydrochloride Chemical compound Cl.NC(=N)C=CC1=CC=CC=C1 FTIRTJVRBRTVKN-UHFFFAOYSA-N 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- IVAPAIWTXULFEK-UHFFFAOYSA-N CCOP(CC([SH2]CC1=CC2=CC=CC=C2C=C1)=N)(OCC)=O Chemical compound CCOP(CC([SH2]CC1=CC2=CC=CC=C2C=C1)=N)(OCC)=O IVAPAIWTXULFEK-UHFFFAOYSA-N 0.000 description 1
- DKHJWWRYTONYHB-UHFFFAOYSA-N CPP Chemical compound OC(=O)C(C)OC1=CC=C(Cl)C=C1 DKHJWWRYTONYHB-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 208000000094 Chronic Pain Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 206010013954 Dysphoria Diseases 0.000 description 1
- 239000004150 EU approved colour Substances 0.000 description 1
- OZLGRUXZXMRXGP-UHFFFAOYSA-N Fluo-3 Chemical compound CC1=CC=C(N(CC(O)=O)CC(O)=O)C(OCCOC=2C(=CC=C(C=2)C2=C3C=C(Cl)C(=O)C=C3OC3=CC(O)=C(Cl)C=C32)N(CC(O)=O)CC(O)=O)=C1 OZLGRUXZXMRXGP-UHFFFAOYSA-N 0.000 description 1
- 102100029458 Glutamate receptor ionotropic, NMDA 2A Human genes 0.000 description 1
- 102100022631 Glutamate receptor ionotropic, NMDA 2C Human genes 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 239000012981 Hank's balanced salt solution Substances 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102000004310 Ion Channels Human genes 0.000 description 1
- 108090000862 Ion Channels Proteins 0.000 description 1
- LBOJYSIDWZQNJS-JKSUJKDBSA-N LSM-5387 Chemical compound C12=CC=CC=C2[C@@]2(C)C3=CC=CC=C3C[C@@H]1N2 LBOJYSIDWZQNJS-JKSUJKDBSA-N 0.000 description 1
- 241000761557 Lamina Species 0.000 description 1
- 241000276489 Merlangius merlangus Species 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 229940099433 NMDA receptor antagonist Drugs 0.000 description 1
- 208000028389 Nerve injury Diseases 0.000 description 1
- 206010029350 Neurotoxicity Diseases 0.000 description 1
- 208000004983 Phantom Limb Diseases 0.000 description 1
- 206010056238 Phantom pain Diseases 0.000 description 1
- YNPNZTXNASCQKK-UHFFFAOYSA-N Phenanthrene Natural products C1=CC=C2C3=CC=CC=C3C=CC2=C1 YNPNZTXNASCQKK-UHFFFAOYSA-N 0.000 description 1
- 206010036376 Postherpetic Neuralgia Diseases 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 206010037211 Psychomotor hyperactivity Diseases 0.000 description 1
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
- 241001632427 Radiola Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 206010044221 Toxic encephalopathy Diseases 0.000 description 1
- DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical compound C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000001977 ataxic effect Effects 0.000 description 1
- HYTACLVSJIFYBY-UHFFFAOYSA-N azane;dichloromethane;methanol Chemical compound N.OC.ClCCl HYTACLVSJIFYBY-UHFFFAOYSA-N 0.000 description 1
- 210000004227 basal ganglia Anatomy 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000004618 benzofuryl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 150000001558 benzoic acid derivatives Chemical class 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 125000006278 bromobenzyl group Chemical group 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 235000011148 calcium chloride Nutrition 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 125000004803 chlorobenzyl group Chemical group 0.000 description 1
- 125000000068 chlorophenyl group Chemical group 0.000 description 1
- 238000013375 chromatographic separation Methods 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 230000003920 cognitive function Effects 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- 125000004987 dibenzofuryl group Chemical group C1(=CC=CC=2OC3=C(C21)C=CC=C3)* 0.000 description 1
- 125000006286 dichlorobenzyl group Chemical group 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 125000006287 difluorobenzyl group Chemical group 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 210000005064 dopaminergic neuron Anatomy 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 229950005455 eliprodil Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000003818 flash chromatography Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 125000004175 fluorobenzyl group Chemical group 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000001640 fractional crystallisation Methods 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 210000001905 globus pallidus Anatomy 0.000 description 1
- 230000000848 glutamatergic effect Effects 0.000 description 1
- 239000003979 granulating agent Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 108091008634 hepatocyte nuclear factors 4 Proteins 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 1
- 125000006289 hydroxybenzyl group Chemical group 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 238000010874 in vitro model Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 125000006480 iodobenzyl group Chemical group 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 230000006742 locomotor activity Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 125000006178 methyl benzyl group Chemical group 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000000329 molecular dynamics simulation Methods 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 230000007659 motor function Effects 0.000 description 1
- 239000003703 n methyl dextro aspartic acid receptor blocking agent Substances 0.000 description 1
- KOZMDAUODFJEOX-UHFFFAOYSA-N n'-[(3-methoxyphenyl)methyl]-3-phenylprop-2-enimidamide;hydrochloride Chemical compound Cl.COC1=CC=CC(CN=C(N)C=CC=2C=CC=CC=2)=C1 KOZMDAUODFJEOX-UHFFFAOYSA-N 0.000 description 1
- IOTSFDBPVQYRQY-UHFFFAOYSA-N n'-benzyl-2-diethoxyphosphorylethanimidamide Chemical compound CCOP(=O)(OCC)CC(N)=NCC1=CC=CC=C1 IOTSFDBPVQYRQY-UHFFFAOYSA-N 0.000 description 1
- NVJVUDZWWZAECK-UHFFFAOYSA-N n'-benzyl-2-diethoxyphosphorylethanimidamide;hydrobromide Chemical compound Br.CCOP(=O)(OCC)CC(=N)NCC1=CC=CC=C1 NVJVUDZWWZAECK-UHFFFAOYSA-N 0.000 description 1
- CVNYACAHNUJYSG-CVDZDCIMSA-N naphthalen-2-ylmethyl (e)-3-phenylprop-2-enimidothioate;hydrobromide Chemical compound Br.C=1C=C2C=CC=CC2=CC=1CSC(=N)\C=C\C1=CC=CC=C1 CVNYACAHNUJYSG-CVDZDCIMSA-N 0.000 description 1
- YPSOERZOMTWUMH-UHFFFAOYSA-N naphthalen-2-ylmethyl 2-diethoxyphosphorylethanimidothioate;hydrobromide Chemical compound Br.C1=CC=CC2=CC(CSC(=N)CP(=O)(OCC)OCC)=CC=C21 YPSOERZOMTWUMH-UHFFFAOYSA-N 0.000 description 1
- 125000004923 naphthylmethyl group Chemical group C1(=CC=CC2=CC=CC=C12)C* 0.000 description 1
- 230000008764 nerve damage Effects 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 230000003961 neuronal insult Effects 0.000 description 1
- 230000006748 neuronal sensitivity Effects 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 231100000228 neurotoxicity Toxicity 0.000 description 1
- 230000007135 neurotoxicity Effects 0.000 description 1
- 230000003040 nociceptive effect Effects 0.000 description 1
- 230000036963 noncompetitive effect Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 108091008757 nuclear thyroid hormone receptors Proteins 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229940006093 opthalmologic coloring agent diagnostic Drugs 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 239000013110 organic ligand Substances 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-M oxalate(1-) Chemical compound OC(=O)C([O-])=O MUBZPKHOEPUJKR-UHFFFAOYSA-M 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 230000001898 pallidal effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 125000006187 phenyl benzyl group Chemical group 0.000 description 1
- 229920000768 polyamine Polymers 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000002953 preparative HPLC Methods 0.000 description 1
- 238000004237 preparative chromatography Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000003518 presynaptic effect Effects 0.000 description 1
- 238000011809 primate model Methods 0.000 description 1
- DBABZHXKTCFAPX-UHFFFAOYSA-N probenecid Chemical compound CCCN(CCC)S(=O)(=O)C1=CC=C(C(O)=O)C=C1 DBABZHXKTCFAPX-UHFFFAOYSA-N 0.000 description 1
- 229960003081 probenecid Drugs 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000002385 psychotomimetic effect Effects 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 239000002287 radioligand Substances 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000011808 rodent model Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 208000020431 spinal cord injury Diseases 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000012258 stirred mixture Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000001117 sulphuric acid Substances 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 230000005062 synaptic transmission Effects 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 229960001367 tartaric acid Drugs 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 108091008646 testicular receptors Proteins 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000005302 thiazolylmethyl group Chemical group [H]C1=C([H])N=C(S1)C([H])([H])* 0.000 description 1
- 125000003866 trichloromethyl group Chemical group ClC(Cl)(Cl)* 0.000 description 1
- 125000006493 trifluoromethyl benzyl group Chemical group 0.000 description 1
Description
AMIDINE DERIVATIVES AS SELECTIVE ANTAGONISTS OF
NMDA RECEPTORS
The present invention relates to a class of amidine derivatives and to their use in the therapy of neurological disorders. In particular, this invention relates to amidines that are useful as selective antagonists of NR2B subunit-containing human N-methyl-D-aspartate (NMDA) receptors. The compounds of the present invention are thus useful for relieving, treating or preventing neurological and neurodegenerative disorders, including pain (and in particular neuropathic pain and headache, specifically migraine), epilepsy, stroke, anxiety, cerebral ischemia, muscular spasms, Alzheimer's Disease, Huntington's Disease and Parkinson's Disease.
Glutamate plays a key role in processes related to chronic pain and pain-associated neurotoxicity, largely acting through NMDA receptors. Much evidence points to the involvement of NMDA receptors in the development and maintenance of neuropathic pain. NMDA receptor antagonists, for example ketamine, dextromethorphan and CPP (3-(2- carboxypiperazin-4-yl)propyl-l-phosphonic acid) have been reported to produce symptomatic relief in a number of neuropathies including postherpetic neuralgia, central pain caused by spinal cord injury and phantom limb pain (Kristensen et al., Pain, 1992, 51, 249-253; Eide et al., Pain, 1995, 61, 221-228; Knox et al., Intensive Care, 1995, 23, 620-622; Max et al., Clin. Neuropharmacol., 1995, 18, 360-368). However, at analgesic doses, psychotomimetic effects that include dizziness, headache, hallucinations, dysphoria and disturbances of cognitive and motor function prohibit their widespread use. To exploit NMDA receptor antagonists as possible treatment options for neuropathic pain, it is necessary to develop new agents with a reduced side-effect profile. Native NMDA receptors are heterodimers composed of an NMDA
Rl (NR1) subunit and at least one NMDA R2 (NR2) subunit. Receptor
cloning strategies have identified multiple NMDA receptor subunits in the CNS including the NR1 subfamily (with eight isoforms derived from alternative splicing of a single gene) and four NR2 subunits (A, B, C, and D) each encoded by a single gene (for review, see Whiting & Priestley, Frontiers of Neurobiology 3, Amino Acid Neurotransmission, Portland Press, 1996, 153-176). Functional receptors have different physiological and pharmacological properties and are differentially distributed in the mammalian CNS, demonstrating the functional heterogeneity of NMDA receptors (Ishii et al., J. Biol. Chem., 1993, 268, 2836-2843; Wenzel et al., NeuroReport, 1995, 7, 45-48; Laurie et al., Brain Res. Mol. Brain Res., 1997, 51, 23-32).
NR1 is found throughout the brain whereas NR2 subunits show a differential distribution. In particular, whereas NR2C is heavily expressed and NR2A is moderately expressed in the cerebellum, there is negligible expression of NR2B in this structure. Immunocytoehemical studies have demonstrated a restricted distribution of the NR2B subunit, with moderate labeling of fibres in laminas I and II of the dorsal horn suggesting a presynaptic location on primary afferent fibres and possible involvement in pain transmission (Boyce et al., Neuropharmacology, 1999, 38, 611-623). The patterns of staining observed in the spinal cord, together with the data showing negligible expression of NR2B in the cerebellum, suggest that NR2B antagonists may possess antinociceptive effects, but with a reduced side effect profile in comparison to non- competitive NMDA antagonists or glycine site antagonists. The NR1/2B selective antagonist CP-101,606 has been reported to possess antinociceptive activity in animal assays of inflammatory hyperalgesia (Taniguchi et al., Br. J. Pharmacol., 1997, 122, 809-812; Sakurada et al, Pharmacol. Biochem. Behaυ., 1998, 59, 339-345). In an animal assay of inflammatory hyperalgesia (carrageenan-induced mechanical hyperalgesia) the NR1/2B antagonists CP-101,606 and Ro 25- 6981 have been shown to possess antinociceptive activity with a
significant separation between analgesic doses and those which induced motor impairment (Boyce et al., Neuropharmacology, 1999, 38, 611-623). NR1/2B antagonists are active in a wide range of animal nociceptive assays, suggesting a clinical utility for other painful conditions in addition to those caused by nerve damage. Moreover, these compounds may have a reduced propensity to elicit the undesirable side-effects (including hallucinations, sedation and ataxia) of ketamine, dextromethorphan and other NMDA ion channel antagonists.
There is a wealth of in vitro and animal model data suggesting that changes in the glutamatergic system (receptors, uptake, release) increase neuronal sensitivity to previous physiological stimuli and thereby trigger secondary neuronal damage. The primary pathology underlying the generation of symptoms in Parkinson's disease is degeneration of dopaminergic neurons of the nigrostriatal pathway (Hornykiewcz, Pharmacol. Rev., 1966, 18, 925-964). Subsequent to loss of striatal dopamine, a series of changes in activity of the basal ganglia circuitry arise, including increased activity in striatal outputs to the lateral segment of the globus pallidus. Overactivity of the striatolateral pallidal pathway is thought to be responsible for the generation of parkinsonian symptoms. It has been demonstrated that selective blockade of NR2B- containing NMDA receptors with the polyamine antagonists ifenprodil and eliprodil cause a significant increase in locomotor activity in a rodent model (Nash et al., Experimental Neurology, 1999, 155, 42-48) and ifenprodil has demonstrated activity in a primate model of Parkinson's disease (Mitchell et al, Behav. Pharmacol., 1995, 6, 492-507).
The present invention provides a class of styryl amidine derivatives which are antagonists of the human NMDA receptor, being selective for those containing the NR2B subunit. As such, they will be active in the treatment of neurological and neurodegenerative disorders, especially neuropathic pain, whilst displaying fewer ataxic and related side-effects associated with other classes of NMDA receptor antagonists.
In addition, the compounds in accordance with the present invention may be useful as radioligands in assays for detecting compounds capable of binding to the NR2B subunit of the human NMDA receptor.
Bio. Med. Chem. Lett., 1998, 8, 199 discloses a series of N-(2- phenethyl)cinnamides which were assayed for antagonism at NMDA receptor subtypes, and found to be potent and selective antagonists of the NR1A/2B subtype.
WO 98/37068 is stated to disclose a class of benzoic acid derivatives and related compounds for use in the treatment of arrhythmia. The present invention provides a compound of formula I, or a pharmaceutically acceptable salt, hydrate or prodrug thereof:
(I)
wherein:
R1 represents Ci-β alkyl, C3-7 cycloalkyl, C3-7 cycloalkyl(Cι-6)alkyl, aryl, aryl(Cι-6)alkyl or heteroaryl(Cι-6)alkyl, any of which groups may be optionally substituted;
R2 represents C3-7 cycloalkyl, aryl or heteroaryl, any of which groups may be optionally substituted; and
R3 represents hydrogen or Ci-β alkyl; or
R1 and R3 are taken together with the intervening nitrogen atom to form an optionally substituted isoquinoline ring.
The groups R1, R2 and R3 may be unsubstituted, or substituted by one or more, suitably one or two, substituents. Examples of optional substituents include Cι-6 alkyl, aryl, halogen, halo(Cι-β)alkyl, dihalo(Cι-6)alkyl, trihalo(Cι-6)alkyl, cyano, cyano(Cι-6)alkyl, hydroxy, hydroxymethyl, C1-6 alkoxy, halo(Cι-6)alkoxy, dihalo(Cι-6)alkoxy and
trihalo(Cι-6)alkoxy. Representative substituents include Cι-6 alkyl, aryl, halogen, trihalo(Cι-6)alkyl, hydroxy, Ci-β alkoxy and trihalo(Cι-6)alkoxy.
As used herein, the expression "Ci-β alkyl" includes methyl and ethyl groups, and straight-chained or branched propyl, butyl, pentyl and hexyl groups. Particular alkyl groups are methyl, ethyl, τi-propyl, isopropyl, tt-butyl, isobutyl, sec-butyl, tert-bvityl, 3-methylbutyl and n- pentyl. Derived expressions such as "Ci-β alkoxy" are to be construed accordingly. Particular values include methoxy and ethoxy.
Typical C3-7 cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl, especially cyclohexyl.
A typical C3-7 cycloalkyl(Cι-6)alkyl group is cyclohexylmethyl.
Typical aryl groups include phenyl and naphthyl, preferably phenyl.
The expression "aryl(Ci.6) alkyl" as used herein includes benzyl, phen lethyl, phenylpropyl and naphthylmethyl.
Suitable heteroaryl groups include pyridinyl, quinolinyl, isoquinolinyl, pyridazinyl, pyrimidinyl, pyrazinyl, quinoxalinyl, furyl, benzofuryl, dibenzofuryl, thienyl, benzthienyl, pyrrolyl, indolyl, pyrazolyl, indazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, imidazolyl, benzimidazolyl, oxadiazolyl, thiadiazolyl, triazolyl and tetrazolyl groups.
Suitable heteroaryl(Cι-6)alkyl groups include furylmethyl, furylethyl, thienylmethyl, thienylethyl, pyrazolylmethyl, pyrazolylethyl, oxazolylmethyl, isoxazolylmethyl, thiazolylmethyl, isothiazolylmethyl, imidazolylmethyl, benzimidazolylmethyl, oxadiazolylmethyl, thiadiazolylmethyl, triazolylmethyl, triazolylethyl, tetrazolylmethyl, pyridinylmethyl, pyridinylethyl, pyridazinylmethyl, pyrimidinylmethyl, pyrazinylmethyl, quinolinylmethyl and isoquinohnylmethyl.
The term "halogen" as used herein includes fluorine, chlorine, bromine and iodine, especially fluorine or chlorine. For use in medicine, the salts of the compounds of formula I will be pharmaceutically acceptable salts. Other salts may, however, be useful in
the preparation of the compounds according to the invention or of their pharmaceutically acceptable salts. Suitable pharmaceutically acceptable salts of the compounds of this invention include acid addition salts which may, for example, be formed by mixing a solution of the compound according to the invention with a solution of a pharmaceutically acceptable acid such as hydrochloric acid, sulphuric acid, methanesulphonic acid, fumaric acid, maleic acid, succinic acid, acetic acid, benzoic acid, oxalic acid, citric acid, tartaric acid, carbonic acid or phosphoric acid. Furthermore, where the compounds of the invention carry an acidic moiety, suitable pharmaceutically acceptable salts thereof may include alkali metal salts, e.g. sodium or potassium salts; alkaline earth metal salts, e.g. calcium or magnesium salts; and salts formed with suitable organic ligands, e.g. quaternary ammonium salts.
The present invention includes within its scope prodrugs of the compounds of formula I above. In general, such prodrugs will be functional derivatives of the compounds of formula I which are readily convertible in vivo into the required compound of formula I. Conventional procedures for the selection and preparation of suitable prodrug derivatives are described, for example, in Design of Prodrugs, ed. H. Bundgaard, Elsevier, 1985.
Where the compounds according to the invention have at least one asymmetric centre, they may accordingly exist as enantiomers. Where the compounds according to the invention possess two or more asymmetric centres, they may additionally exist as diastereoisomers. It is to be understood that all such isomers and mixtures thereof in any proportion are encompassed within the scope of the present invention.
Suitable values for the substituent R1 in the compounds according to the invention include methyl, ethyl, i-propyl, isopropyl, ? -butyl, isobutyl, sec-butyl,
3-methylbutyl, λt-pentyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclohexylmethyl, phenyl, naphthyl, benzyl, phenylethyl, phenylpropyl, pyridinyl, furyl, thienyl, pyrrolyl, indolyl,
triazolyl, furylmethyl, thienylmethyl and pyridinylmethyl, any of which groups may be substituted by one or more substituents. Typical values of R1 include n.-butyl, isobutyl, 3-methylbutyl, ti-pentyl, cyclohexyl, cyclohexylmethyl, phenyl, benzyl, phenylethyl, phenylpropyl, furylmethyl, thienylmethyl and pyridinylmethyl, any of which groups may be optionally substituted by one or more substituents.
Specific illustrations of particular substituents on the group R1 include methyl, ethyl, n.-propyl, phenyl, fluoro, trifluoromethyl, chloro, trichloromethyl, bromo, tribromomethyl, iodo, cyano, cyanomethyl, hydroxy, hydroxymethyl, methoxy, ethoxy and trifluoromethoxy.
More specific illustrations of particular substituents on the group R1 include methyl, phenyl, fluoro, chloro, bromo, fluoro, iodo, trifluoromethyl, hydroxy, methoxy, ethoxy and trifluoromethoxy. Representative values of R1 include 7 -butyl, isobutyl, 3- methylbutyl, 7i-pentyl, cyclohexyl, cyclohexylmethyl, phenyl, benzyl, methylbenzyl, phenylbenzyl, fluorobenzyl, difluorobenzyl, chlorobenzyl, dichlorobenzyl, bromobenzyl, iodobenzyl, trifluoromethylbenzyl, hydroxybenzyl, methoxybenzyl, ethoxybenzyl, trifLuoromethoxybenzyl, phenylethyl, phenylpropyl, furylmethyl, thienylmethyl and pyridinylmethyl.
Suitable values for the substituent R2 in the compounds according to the invention include cyclopentyl, cyclohexyl, phenyl, naphthyl, pyridinyl, furyl, thienyl and pyrrolyl, any of which groups may be optionally substituted by one or more substituents. Typical values of R2 include cyclohexyl, phenyl and furyl, any of which groups may be optionally substituted by one or more substituents.
Specific illustrations of particular substituents on the group R2 include methyl, ethyl, fluoro, chloro, bromo, cyano, hydroxy, methoxy and ethoxy. More specific illustrations of particular substituents on the group
R2 include fluoro, chloro and methoxy.
Representative values of R2 include cyclohexyl, phenyl, fluorophenyl, difluorophenyl, chlorophenyl, methoxyphenyl and furyl. Preferred values of R2 include phenyl, fluorophenyl and difluorophenyl.
Suitable values of R3 include hydrogen and methyl, preferably hydrogen.
A particular sub-class of compounds according to the invention is represented by the compounds of formula IIA, and pharmaceutically acceptable salts, hydrates or prodrugs thereof:
wherein R2 and R3 are as defined above;
R21 represents hydrogen, Ci-e alkyl, aryl, halogen, trihalo(Ci-6) alkyl, hydroxy, Cι-6 alkoxy or trihalo(Cι-6) alkoxy; and R22 represents hydrogen or halogen.
Particular values of R21 include hydrogen, methyl, phenyl, fluoro, chloro, bromo, iodo, trifluoromethyl, hydroxy, methoxy, ethoxy and trifluoromethoxy.
Suitably, R22 represents hydrogen or chloro, especially hydrogen. Another sub-class of compounds according to the invention is represented by the compounds of formula IIB, and pharmaceutically acceptable salts, hydrates or prodrugs thereof:
wherein R1 and R3 are as defined above;
R31 represents hydrogen, Ci-β alkyl, halogen or Ci-β alkoxy; and
R32 represents hydrogen or halogen.
Particular values of R31 include hydrogen, fluoro, chloro and methoxy, especially fluoro.
Suitably, R32 represents hydrogen or fluoro, especially hydrogen.
A further sub-class of compounds according to the invention is represented by the compounds of formula IIC, and pharmaceutically acceptable salts, hydrates or prodrugs thereof:
wherein R3, R21, R22, R31 and R32 are as defined above. Another sub-class of compounds according to the invention is represented by the compounds of formula IID, and pharmaceutically acceptable salts, hydrates or prodrugs thereof:
wherein R3, R21, R22 and R31 are as defined above.
Specific compounds within the scope of the present invention include:
(S)-N-(3-iodobenzyl)cinnamamidine;
(E) -N- (benzyl)cinnamamidine ;
(£)-N-(4-chlorobenzyl)cinnamamidine;
(I^-N-(2-chlorobenzyl)cinnamamidine; (jB)-N-(3-chlorobenzyl)cinnamamidine;
(JE)-N-(4-fluorobenzyl)cinnamamidine;
(S)-N-(4-trifluoromethylbenzyl)cinnamamidine;
(E) -N- (4-methoxybenzyl)cinnamamidine ;
(JδJ)-N-(4-methylbenzyl)cinnamamidine; (£J)-N-(3-methylbenzyl)cinnamamidine;
(£)-N-(2-methylbenzyl)cinnamamidine;
(£)-N-(3,4-dichlorobenzyl)cinnamamidine;
(Z^-N~(2-phenylethyl)cinnamamidine;
( )-N-(jR)- -methylbenzylcinnamamidine; (Z^-N-(S)-α-methylbenzylcmnamamidine;
(E -N-(3-trifluoromethylbenzyl)cinnamamidine;
(E)-N-(3,5-dichlorobenzyl)cinnamamidine;
(S)-N-(2-methoxybenzyl)cinnamamidine;
(£J)-N-(3-methoxybenzyl)cinnamamidine; (JB)-N-(2-trifluoromethylbenzyl)cinnamamidine;
(£)-N-(2,5-dichlorobenzyl)cinnamamidine;
( )-N-(3-bromobenzyl)cinnamamidine;
(£ -N-(4-pyridylmethyl)cinnamamidine;
( )-N-methyl-N-benzylcinnamamidine; (E)-N-(2, 3-dichlorobenzyl)cinnamamidine;
(£)-N-(cyclohexylmethyl)cinnamamidine;
(E) -N- (isobutyl)cinnamamidine ;
(E) -N- (/ -butyl)cinnamamidine ;
(E)-N- (2-trifluoromethoxybenzyl)cinnamamidine ; (£)-N-(3-thienylmethyl)cinnamamidine;
(E)-N-(2-bromobenzyl)cinnamamidine;
(l£)-N-(2-ethoxybenzyl)cinnamamidine;
(i£)-N-(2-phenylbenzyl)cinnamamidine;
(S)-N-(2-furylmethyl)cinnamamidine;
(J5)-N-(cyclohexyl)cinnamamidine; (£ )-N-(3-nτethyl-l-butyl)cinnamamidine;
(S)-2-(3-phenyl-l-imino-2-propenyl)-l,2,3,4-tetrahydroisoquinoline;
(^)-N-(tz-pentyl)cinnamamidine;
(jB)-N-(3-phenyl-l-propyl)cinnamamidine;
(E)-N-(2-hydroxybenzyl)cinnamamidine; (Z?)-N-phenylcinnamamidine;
(Z -N-benzyl-2-chlorocinnamamidine;
(E)-N-benzyl-3-chlorocinnamamidine;
(EJ)-N-benzyl-4-chlorocinnamamidine;
(S)-N-benzyl-4-fluorocinnamamidine; (i£)-N-benzyl-4-methoxycinnamamidine;
(i -N-benzyl-3-methoxycinnamamidine;
(Z -N-benzyl-2-methoxycinnamamidine;
(S)-N-benzyl-3,4-difluorocinnamamidine;
(2£)-N-benzyl-3-cyclohexaneacrylamidine; and pharmaceutically acceptable salts, hydrates and prodrugs thereof.
The compounds of formula I, and the pharmaceutically acceptable salts, hydrates and prodrugs thereof, are useful for the relief of neurological and neurodegenerative disorders, including pain (and in particular neuropathic pain and headache, specifically migraine), epilepsy, stroke, anxiety, cerebral ischemia, muscular spasms, Alzheimer's Disease,
Huntington's Disease and Parkinson's Disease.
For the treatment of any of these neurological and neurodegenerative diseases, a compound of formula I is administered in an amount that is effective to treat or prevent the said disease or condition. The compound may be administered orally, topically, parenterally, by inhalation spray or rectally, in dosages containing conventional non-toxic
pharmaceutically acceptable diluents, adjuvants and vehicles. The term "parenteral" as used herein includes subcutaneous, intravenous, intramuscular, intradermal, epidural, and intrasternal injection or infusion techniques. The therapeutic dose of the compound of formula I will vary with the nature or severity of the condition to be treated, the particular compound selected, its route of administration and other factors. It will also vary according to the age, weight and response of the individual patient. A representative dose ranges from about 0.001 mg/kg per day to about 100 mg/kg per day.
In another aspect, the present invention provides a pharmaceutical composition comprising a compound of formula I or a pharmaceutically acceptable salt, hydrate or prodrug thereof in combination with a pharmaceutically acceptable carrier. Optionally other therapeutic ingredients may be included as well. Examples of dosage forms include tablets, troches, dispersions, suspensions, solutions, capsules, creams, ointments and aerosols.
The compositions may be presented in multiple dosage containers or in unit dosage form and prepared by methods well-known in the art of pharmacy.
The compounds of formula I can be combined as the active ingredient with the pharmaceutical carrier according to conventional pharmaceutical compounding techniques. The carrier may take a wide variety of forms depending on the form desired. In preparing oral dosage forms, any of the usual pharmaceutical media may be employed, such as, for example, water, alcohols, oils, flavouring agents, preservatives and colouring agents in the case of oral liquid preparations such as, for example, suspensions, elixirs and solutions; or starches, sugars, microcrystalline cellulose, diluents, granulating agents, lubricants, binders and disintegrating agents in the case of oral solid preparations such as, for example, powders, capsules and tablets. Solid oral
preparations are preferred over liquid preparations. If desired, tablets may be coated by standard aqueous or nonaqueous techniques.
Examples of suitable dosage units typically range from about 0.01 mg to about 1.0 g of the active ingredient. The diseases or conditions described herein may be effectively treated by the administration of from about 0.01 to about 50 mg of the compound per kilogram of body weight per day, or alternatively about 0.5 mg to about 3.5 g per patient per day.
The active ingredient may be combined with the carrier materials to produce the dosage form. For example, a formulation intended for oral administration to humans may contain from about 0.5 mg to about 5 g of the compound, compounded with an appropriate and convenient amount of carrier material which may vary from about 5 to about 95 percent of the total composition. Dosage units will generally contain between from about 1 mg to about 1000 mg of active ingredient, typically 25 mg, 50 mg, 100 mg, 200 mg, 300 mg, 400 mg, 500 mg, 600 mg, 800 mg or 1000 mg.
It will be understood that the specific dose level for any particular patient depends upon a variety of factors including the age, body weight, general health, sex, diet, time of administration, route of administration, rate of excretion, drug combination and the severity of the particular disease or condition undergoing therapy.
The compounds of formula I as defined above may be prepared by a process which comprises reacting a compound of formula III with a compound of formula IV:
(III) (IV)
wherein R1, R2 and R3 are as defined above, and Rx represents Ci-β alkyl, preferably methyl or ethyl.
The reaction between compounds III and IV is conveniently effected by stirring the reactants in a suitable solvent, typically methanol.
The intermediates of formula III may be prepared -by reacting a compound of formula V with a compound of formula VI:
NC
■R* Rx ■OH
(V) (VI)
wherein R2 and Rx are as defined above.
The reaction between the compounds of formula V and VI is conveniently effected by stirring the reactants in the presence of hydrogen chloride, in a suitable solvent, typically ether.
In another procedure, the compounds of formula I as described above may be prepared by a process which comprises reacting a compound of formula IV as defined above with a compound of formula VII:
(VII)
wherein R2 is as defined above.
The reaction between compounds IV and VII is conveniently effected by stirring the reactants in a suitable solvent, typically chloroform or ethanol, at room temperature.
The intermediates of formula VII above may be prepared by reacting a compound of formula VIII with a compound of formula IX:
(VTII) (IX)
wherein R2 is as defined above, and X represents a halogen atom, e.g. bromo.
The reaction between compounds VTII and IX is conveniently effected by refluxing the reactants in a suitable solvent, typically chloroform.
The intermediates of formula IX above may be prepared by reacting the compound of formula X with a compound of formula XI:
(X) (XI)
wherein R2 is as defined above. The reaction between compounds X and XI is conveniently effected by treating compound X with a strong base, e.g. sodium hydride, in the presence of a suitable solvent, typically THF, then adding compound XI and stirring the reaction mixture at a temperature between 0°C and room temperature. In a further procedure, the compounds of formula I as defined above may be prepared by a process which comprises reacting a compound of formula XI as defined above with a compound of formula XII:
(XII)
wherein R1 and R3 are as defined above.
The reaction between compounds XI and XII is conveniently effected under basic conditions. For example, the reactants may be stirred with sodium hydroxide at room temperature in a suitable solvent, e.g. dichlorome thane, typically in the presence of tetra-ra-butylammonium bromide; or the reactants may be heated with potassium carbonate at reflux in a suitable solvent, typically tetrahydrofuran. The intermediates of formula XII above may be prepared by reacting a compound of formula IV as defined above with a compound of formula XIII:
(XIII)
under conditions analogous to those described above for the reaction between compounds IV and VII.
The intermediates of formula XIII above may be prepared by reacting a compound of formula VIII with a compound of formula X, under conditions analogous to those described above for the reaction between compounds VIII and IX.
Where they are not commercially available, the starting materials of formula IV, V, VI, VIII, X and XI may be prepared by methods
- 17 -
analogous to those described in the accompanying Examples, or by standard methods well known from the art.
It will be understood that any compound of formula I initially obtained from any of the above processes may, where appropriate, subsequently be elaborated into a further compound of formula I by techniques known from the art.
Where the above-described processes for the preparation of the compounds according to the invention give rise to mixtures of stereoisomers, these isomers may be separated by conventional techniques such as preparative chromatography or crystallisation. The novel compounds may be prepared in racemic form, or individual enantiomers may be prepared either by enantiospecifϊc synthesis or by resolution. The novel compounds may, for example, be resolved into their component enantiomers by standard techniques such as preparative HPLC, or the formation of diastereomeric pairs by salt formation with an optically active acid, such as (-)-di-p-toluoyl-d-tartaric acid and/or (+)-di- -toluoyl-l-tartaric acid, followed by fractional crystallization and regeneration of the free base. The novel compounds may also be resolved by formation of diastereomeric esters or amides, followed by chromatographic separation and removal of the chiral auxiliary.
During any of the above synthetic sequences it may be necessary and/or desirable to protect sensitive or reactive groups on any of the molecules concerned. This may be achieved by means of conventional protecting groups, such as those described in Protective Groups in Organic Chemistry, ed. J.F.W. McOmie, Plenum Press, 1973; and T.W. Greene & P.G.M. Wuts, Protective Groups in Organic Synthesis, John Wiley & Sons, 1991. The protecting groups may be removed at a convenient subsequent stage using methods known from the art.
The following Examples illustrate the preparation of compounds according to the invention.
The following assays are used to demonstrate biological activity and utility for the compounds of formula I.
[3H| -Ifenprodil binding to recombinant human NRla/NR2B receptors Ifenprodil is an NMDA receptor antagonist which acts through a distinct modulatory site from those of glutamate, glycine and MK-801 (dizocilpine) and is selective for NR2B-containing receptors (Grimwood et al., J. Neurochem., 1996, 66, 2589-2595). [3H] -Ifenprodil binding to ceU membranes expressing recombinant human NRla NR2B receptors is determined essentially as described by Grimwood et al, NeuroReport, 1999, 10, 461-465.
The compounds of the accompanying Examples were tested in the above assay, and all were found to demonstrate a 50% inhibition of [3H]- ifenprodil binding at a concentration of 5 μM or less.
Functional Ca++ antagonism assay-FLIPR
Human NRla/2B receptor transfected cells are plated in a 96-well format and grown for one day in normal growth media (Dulbeccos MEM with Na pyruvate). NRla/2B expression in these cells is induced by the addition of dexamethasone in the presence of ketamine for 16-24 hours. After receptor induction cells are washed with assay buffer (Hanks balanced salt solution (HBSS-Mg free) containing 20 M HEPES, 0.1% BSA, 2 mM CaCl2 and 250 μM probenecid). Each 96 well cell plate is loaded with the Ca^ sensitive dye Fluo-3 (Molecular Probes, Inc.) in assay buffer. The cells are then washed with assay buffer leaving them in 100 μl buffer. Test compounds in solution are pipetted by FLIPR (Fluorometric Imaging Plate Reader, Molecular Dynamics) for 2 min pretreatment. During this time the fluorescence intensity is recorded (excitation at 488 nm and emission at 530 nm). The glutamate/glycine 50 μl agonist solution (final concentration 1 μM/1 μM) is then added by FLIPR into each well already containing 150 μl of buffer (containing the test compound or
vehicle) and the fluorescence is continuously monitored for 10 min. Fluorescence values in the presence of an antagonist are compared to those for the agonist alone.
Of those compounds of the accompanying Examples which were tested in this assay, all were found to possess an EC50 value of 10 μM or less.
Carrageenan-induced mechanical hyperalgesia in rats
The ability of test compounds to reverse carrageenan induced hyperalgesia can be determined using the method described by Boyce et al, Neuropharmacology, 1994, 33, 1609-1611.
EXAMPLE 1
(J?)-N-(3-Iodobenzyl)cinnamamidine hvdrochloride
3-Iodobenzylamine (85μl, 0.64mmol) was added to a solution of (E)- ethyl cinnamimidate hydrochloride (112.9mg, 0.571mmol) [prepared by the method of E.C. Roberts and Y.F. Shealy, J. Ret. Chem. 1974, 11, 547] in methanol (1ml) and the mixture stirred at room temperature overnight (18 hours). The mixture was diluted with diethyl ether (3ml), the crystalline product collected under suction, washed with methanol-diethyl ether (1:3) then diethyl ether and dried in vacuo to give the title product as a white solid (173mg, 76%); 6H (360MHz, DMSO-d6) 4.60 (2H, d, J 5.2Hz, ArCH2N), 6.89 (IH, d, J 16.5Hz, CH=CHPh), 7.22 (1Η, t, J 7.8Ηz, ArH), 7.46 (IH, d, J 7.8Hz, ArH), 7.50 (3H, m, ArH), 7.60 (2H, m, ArH), 7.73 (IH, d, J 7.9Hz, ArH), 7.83 (IH, s, ArH), 7.92 (IH, d, J 16.5Hz, CH=CHPh), 9.03 (IH, br s, NH), 9.52 (IH, br s, NH), 10.26 (IH, br s, NH); m/z (ES+) 363 ([M+H]+).
The following Examples were prepared in an analogous process to the one described above:
EXAMPLE 2
(^-N- BenzvDcinnamamidine hydrochloride (Found: C, 70.35; H, 6.16; N, 10.30. Cι6H17ClN2 requires C, 70.45;
H, 6.28; N, 10.27%); δH (360MHz, DMSO-d6) 4.64 (2H, s, PhCH2N), 6.93 (IH, d, J 16.5Hz, CH=CHPh), 7.37 (1Η, m, ArΗ), 7.42 (4Η, m, ArH), 7.49 (3H, m, ArH), 7.60 (2H, m, ArH), 7.96 (IH, d, J 16.5Hz, CH=CHPh), 9.04 (IH, br s, NH), 9.54 (IH, br s, NH), 10.31 (IH, br s, NH); m/z (ES+) 237 ([M+HJ+).
EXAMPLE 3
(■E)-N-(4-Chlorobenzyl)cinnamamidine hydrochloride δH (360MHz, DMSO-de) 4.63 (2H, s, ArCH2N), 6.90 (IH, d, J 16.4Hz,
CH=CHPh), 7.48 (7H, m, ArH), 7.60 (2H, m, ArH), 7.93 (IH, d, J 16.4Hz, CH=CHPh), 9.04 (IH, br s, NH), 9.53 (IH, br s, NH), 10.30 (IH, br s, NH); m/z (ES+) 271/273 ([M+H]+).
EXAMPLE 4
(£)-N-(2-Chlorobenzyl)cinnamamidine hydrochloride δH (360MHz, DMSO-de) 4.68 (2H, s, ArCH2N), 6.91 (IH, d, J 16.5Hz, CH=CHPh), 7.42-7.62 (9H, m, ArH), 7.94 (IH, d, J 16.5Hz, CH=CHPh), 9.08 (IH, br s, NH), 9.58 (IH, br s, NH), 10.10 (IH, br s, NH); m/z (ES+) 271/273 (jM+H]+).
EXAMPLE 5
( -N-(3-Chlorobenzyl)cinnamamidine hydrochloride
- 21 -
δH (360MHz, DMSO-de) 4.65 (2H, s, PhCH2N), 6.91(1H, d, J 16.5Hz, CH=CHPh), 7.47 (7H, m, ArH), 7.60 (2H, m, ArH), 7.95 (IH, d, J 16.5Hz, CH=CHPh), 9.07 (IH, br s, NH), 9.55(1H, br s, NH), 10.35 (IH, br s, NH); m/z (ES+) 271/273 ([M+H]+).
EXAMPLE 6
( )-N-(4-Fluorobenzyl)cinnamamidine hydrochloride δH (360MHz, DMSO-de) 4.61 (2H, s, ArCH2N), 6.89 (IH, d, J 16.4Hz, CH=CHPh), 7.26 (2Η, m, ArH), 7.50 (5H, m, ArH), 7.59 (2H, m, ArH), 7.92 (IH, d, J 16.5Hz, CH=CHPh), 9.03 (IH, br s, NH), 9.51 (IH, br s, NH), 10.26 (IH, br s, NH); m/z (ES+) 255 (|M-i-H]+).
EXAMPLE 7
( )-N-(4-Trifluoromethylbenzyl cinnamamidine hydrochloride δH (360MHz, DMSO-de) 4.75 (2H, s, ArCH2N), 6.91 (IH, d, J 16.5Hz, CH=CHPh), 7.51 (3H, m, ArH), 7.63 (4H, m, ArH), 7.80 (2H, m, ArH), 7.94 (IH, d, J 16.5Hz, CH=CHPh); m/z (ES+) 305 ([M+H]+).
EXAMPLE 8
( -N-(4-Methoxybenzyl)cinnamamidine hydrochloride δH (360MHz, DMSO-de) 3.76 (3H, s, OCH3), 4.54 (2H, s, ArCH2N), 6.88 (IH, d, J 16.5Hz, CH=CHPh), 6.98 (2H, m, ArH), 7.37 (2H, m, ArH), 7.49 (3H, m, ArH), 7.59 (2H, m, ArH), 7.92 (IH, d, J 16.5Hz, CH=CHPh); m/z (ES+) 267([M+H]+).
EXAMPLE 9
(E)-N-(4-Methylbenzyl)cinnamamidine hydrochloride
δH (360MHz, DMSO-de) 2.31 (3H, s, ArCH3), 4.57 (2H, s, ArCH2N), 6.91(1H, d, J 16.5Hz, CH=CHPh), 7.22 (2H, m, ArH), 7.35 (2H, m, ArH), 7.50 (3H, m, ArH), 7.59 (2H, m, ArH), 7.94 (IH, d, J 16.5Hz, CH=CHPh), 8.99 (IH, br s, NH), 9.51 (IH, br s, NH), 10.24 (IH, br s, NH); m/z (ES+) 251([M+H]+).
EXAMPLE 10
( -N-(3-Methylbenzyl)cinnamamidine hydrochloride δH (360MHz, DMSO-de) 2.33 (3H, s, ArCHs), 4.58 (2H, s, ArCH2N),
6.91(1H, d, J 16.4Hz, CH=CHPh), 7.15-7.32 (4Η, m, ArH), 7.49 (3H, m, ArH), 7.60 (2H, m, ArH), 7.91(1H, d, J 16.5Hz, CH=CHPh); m/z (ES+) 251([M+H]+).
EXAMPLE 11
( -N-(2-Methylbenzyl)cinnamamidine hydrochloride δH (360MHz, DMSO-de) 2.33 (3H, s, ArCHs), 4.60 (2H, s, ArCH2N), 6.99 (IH, d, J 16.5Hz, CH=CHPh), 7.26 (4H, m, ArH), 7.50 (3H, m, ArH), 7.60 (2H, m, ArH), 8.00 (IH, d, J 16.5Hz, CH=CHPh); m/z (ES+) 251(IM+H]+).
EXAMPLE 12
Z?)-N-(3,4-Dichlorobenzyl)cinnamamidine hydrochloride δH (360MHz, DMSO-de) 4.66 (2H, s, ArCH2N), 6.94 (IH, d, J 16.5Hz, CH=CHPh), 7.47 (4H, m, ArH), 7.60 (2H, m, ArH), 7.69 (IH, , ArH), 7.77 (IH, m, ArH), 7.98 (IH, d, J 16.5Hz, CH=CHPh), 9.14 (IH, br s, NH), 9.61 (IH, br s, NH), 10.48 (IH, br s, NH); m/z (ES+) 305/307([M+H]+).
EXAMPLE 13
(Jg)-N-(2-Phenylethyl')cinnamamidine hydrochloride δH (360MHz, DMSO-de) 2.95 (2H, t, NCH2CH2Ph), 3.61 (2H, t, NCH2CH2PI1), 6.86 (IH, d, J 16.5Hz, CH=CHPh), 7.34 (5H, m, ArH), 7.50 (3H, m, ArH), 7.58 (2H, m, ArH), 7.86 (IH, d, J 16.5Hz, CH=CHPh), 8.85 (IH, br s, NH), 9.37 (IH, br s, NH), 9.94 (IH, br s, NH); m/z (ES+) 251(PV1+H]+).
EXAMPLE 14
( -N-(ffl-α-Methylbenzylcinnamamidine hydrochloride δH (360MHz, DMSO-de) 1.57 (3H, d, J 6.7Hz, NCH(CH3)Ph), 5.11 (IH, m, NCH(CH3)Ph), 6.96 (IH, d, J 16.5Hz, CH=CHPh), 7.31-7.49 (8Η, m, ArH), 7.61 (2H, m, ArH), 7.91 (IH, d, J 16.5Hz, CH=CHPh); m/z (ES+) 251flTVI+H]+).
EXAMPLE 15
(E -N-(<S)-α-Methylbenzylcinnamamidine hydrochloride δH (360MHz, DMSO-de) 1.57 (3H, d, J 6.7Hz, NCH(CHs)Ph), 5.17 (IH, m, NCH(CH3)Ph), 7.05 (IH, d, J 16.5Hz, CH=CHPh), 7.30-7.52 (8H, m, ArH), 7.60 (2H, m, ArH), 7.99 (IH, d, J 16.5Hz, CH=CHPh); m/z (ES+) 251([M+H]+).
EXAMPLE 16
( )-N-(3-Trifluoromethylbenzyl)cinnamamidine hydrochloride δH (360MHz, DMSO-de) 4.75 (2H, s, ArCH2N), 6.93 (IH, d, J 16.5Hz, CH=CHPh), 7.50 (3Η, m, ArH), 7.59-7.77 (5H, m, ArH), 7.85 (IH, m, ArH),
7.97 (IH, d, J 16.5Hz, CH=CHPh), 9.13 (IH, br s, NH), 9.60 (IH, br s, NH), 10.43 (IH, br s, NH); m/z (ES+) 305 ([M+H]+).
EXAMPLE 17
(ϋ7)-N- (3 , 5-Dichlorobenzyl)cinnamamidine hydrochloride δH (360MHz, DMSO-de) 4.67 (2H, s, ArCH2N), 6.92 (IH, d, J 16.5Hz, CH=CHPh), 7.50 (3H, m, ArH), 7.55 (2H, m, ArH), 7.60 (3H, m, ArH), 7.96 (IH, d, J 16.5Hz, CH=CHPh), 9.13 (IH, br s, NH), 9.60 (IH, br s, NH), 10.44 (IH, br s, NH); m/z (ES+) 305/307([M+H]+).
EXAMPLE 18
( -N-(2-Methoxybenzyl)cinnamamidine hydrochloride δH (360MHz, DMSO-de) 3.85 (3H, s, ArOCHs), 4.54 (2H, s, ArCH2N),
6.92 (IH, d, J 16.5Hz, CH=CHPh), 6.99 (1Η, m, ArΗ), 7.09 (1Η, d, ArΗ), 7.31-7.39 (2Η, m, ArH), 7.49 (3H, m, ArH), 7.59 (2H, m, ArH), 7.94 (IH, d, J 16.5Hz, CH=CHPh), 8.91 (IH, br s, NH), 9.53 (IH, br s, NH), 9.96 (IH, br s, NH); m/z (ES+) 267([M+H]+).
EXAMPLE 19
(fi N-(3-Methoxybenzyl)cinnamamidine hydrochloride δH (360MHz, DMSO-de) 3.77 (3H, s, ArOCHs), 4.59 (2Η, d; ArCH2N), 6.91-7.04 (4H, m, ArH, CH=CHPh), 7.33 (1Η, m, ArΗ), 7.49 (3Η, m, ArH), 7.59 (2H, m, ArH), 7.96 (IH, d, J 16.5Hz, CH=CHPh), 9.03 (IH, br s, NH), 9.54 (IH, br s, NH), 10.33. (IH, br s, NH); m/z (ES+) 267([M+H]+).
EXAMPLE 20
(E)-N- (2-Trifluoromethylbenzyl cinnamamidine hydrochloride
δH (360MHz, DMSO-de) 4.77 (2H, s, ArCH2N), 6.93 (IH, d, J 16.5Hz, CH=CHPh), 7.50 (3Η, m, ArH), 7.62 (4H, m, ArH), 7.77 (IH, m, ArH),7.84 (IH, m, ArH), 7.96 (IH, d, J 16.5Hz, CH=CHPh), 9.18 (IH, br s, NH), 9.68 (IH, br s, NH), 10.12 (IH, br s, NH); m/z (ES+) 305 ([M+HJ+).
EXAMPLE 21
(E) -N-(2, 5-Dichlorobenzyl)cinnamamidine hydrochloride δH (360MHz, DMSO-de) 4.68 (2H, s, ArCH2N), 6.98 (IH, d, J 16.1Hz, CH=CHPh), 7.50-7.59 (8Η, m, ArH), 8.01 (IH, d, J 16.6Hz, CH=CHPh); m/z (ES+) 305/307(|M+H]+).
EXAMPLE 22
( -N-(3-Bromobenzyl)cinnamamidine hydrochloride δH (360MHz, DMSO-de) 4.64 (2H, d, ArCH2N), 6.92 (IH, d, J 16.5Hz, CH=CHPh), 7.28-7.67 (9Η, m, ArH), 7.96 (IH, d, J 16.5Hz, CH=CHPh), 9.08 (IH, br s, NH), 9.57 (IH, br s, NH), 10.38 (IH, br s, NH); m/z (ES+) 315/317 ([M+H]+).
EXAMPLE 23
(£)-N-(4-Pyridylmethyl)cinnamamidine hydrochloride δH (360MHz, DMSO-de) 4.99 (2H, d, ArCH2N), 7.03 (IH, d' J 16.4Hz, CH=CHPh), 7.52 (3Η, m, ArH), 7.62 (2H, m, ArH), 7.95 (2H, m, ArH), 8.08 (IH, d, J 16.4Hz, CH=CHPh), 8.88 (2H, d, ArH), 9.38 (IH, br s, NH), 9.78 (IH, br s, NH), 10.86 (IH, br s, NH); m/z (ES+) 238 (PVI+H]+).
EXAMPLE 24
( -N-Methyl-N-benzylcinnamamidine hydrochloride
- 26 -
δH (400MHz, DMSO-de, 340K) 3.11 (3H, s, NCH3), 4.93 (2Η, s, ArCH2N), 7.17 (IH, d, J 16.0 Hz, CH=CHPh), 7.32-7.48 (8Η, m, ArH), 7.61- 7.72 (3H, m, ArH, CH=CHPh); m/z (ES+) 251 flM+H]+).
EXAMPLE 25
(E)-N-(2, 3-Dichlorobenzyl)cinnamamidine hydrochloride δH (360MHz, DMSO-de) 4.72 (2H, s, ArCH2N), 6.97 (IH, d, J 16.4Hz, CH=CHPh), 7.44 (2Η, m, ArH), 7.50 (3H, m, ArH), 7.61 (2H, m, ArH), 7.68 (IH, , ArH), 8.00 (IH, d, J 16.5Hz, CH=CHPh), 9.67 (3H, br s, 3 x NH); m/z (ES+) 305/307([M+H]+).
EXAMPLE 26
( -N-(Cycloheχylmethyl)cinnamamidine hydrochloride δH (360MHz, DMSO-d6) 0.95-1.02 (2H, m), 1.18-1.24 (3H, m), 1.65- 1.79 (6H, m), 3.20 (2H, t, CH2N), 6.92 (IH, d, J 16.4Hz, CH=CHPh), 7.49 (3Η, m, ArH), 7.59 (2H, m, ArH), 7.88 (IH, d, J 16.5Hz, CH=CHPh), 8.76 (IH, br s, NH), 9.32 (IH, br s, NH), 9.83 (IH, br s, NH); m/z (ES+) 243([M+H]+).
EXAMPLE 27
( -N-(Isobutyl cinnamamidine hydrochloride δH (360MHz, DMSO-de) 0.95 (6H, m), 1.95 (IH, m), 3.18 (2H, d,
CH2N), 6.98 (IH, d, J 16.5Hz, CH=CHPh), 7.49 (3Η, m, ArH), 7.59 (2H, m, ArH), 7.92 (IH, d, J 16.5Hz, CH=CHPh); m/z (ES+) 203(| +H]+).
EXAMPLE 28
( -N-(7i-Butyl)cinnamamidine hydrochloride
δH (360MHz, DMSO-de) 0.92 (3H, m), 1.39 (2H, ), 1.59 (2H, m), 3.32 (2H, s, CH2N), 6.90 (IH, d, J 16.5Hz, CH=CHPh), 7.49 (3H, m, ArH), 7.58 (2H, m, ArH), 7.89 (IH, d, J 16.5Hz, CH=CHPh), 8.76 (IH, br s, NH), 9.34 (IH, br s, NH), 9.88 (IH, br s, NH); m/z (ES+) 203([M+H]+).
EXAMPLE 29
( -N-(2-Trifluoromethoχybenzyl)cinnamamidine hydrochloride δH (360MHz, DMSO-de) 4.69 (2H, d, ArCH2N), 6.91 (IH, d, J 16.5Hz, CH=CHPh), 7.45-7.62 (9H, m, ArH), 7.94 (IH, d, J 16.5Hz, CH=CHPh), 9.14 (IH, br s, NH), 9.63 (IH, br s, NH), 10.11 (IH, br s, NH); m/z (ES+) 321 ([M+H]+).
EXAMPLE 30
( -N-(3-ThienylmethyT)cinnamamidine hydrochloride δH (360MHz, DMSO-de) 4.83 (2H, d, ArCH2N), 6.84 (IH, d, J 16.4Hz, CH=CHPh), 7.07 (2Η, m, ArH), 7.23 (2H, m, ArH), 7.56 (4H, m, ArH), 7.87 (IH, d, J 16.5Hz, CH=CHPh), 9.48 (IH, br s, NH), 9.50 (IH, br s, NH), 10.22 (IH, br s, NH); m/z (ES+) 243 ([M+H]+).
EXAMPLE 31
( -N-(2-Bromobenzyl)cinnamamidine hydrochloride δH (250MHz, DMSO-de) 4.64 (2H, s, ArCH2N), 6.90 (IH, d, J 16.5Hz, GH=CHPh), 7.36 (1Η, , ArΗ), 7.49 (5Η, m, ArH), 7.60 (2H, m, ArH), 7.74 (IH, d, J 10.9Hz, ArH), 7.92 (IH, d, J 16.5Hz, CH=CHPh); m/z (ES+) 315/317 (| +H]+).
EXAMPLE 32
( -N-(2-Ethoxybenzyl)cinnamamidine hydrochloride δH (360MHz, DMSO-de) 1.35 (3H, t, CH2CH3), 4.09 (2Η, q, CH2CH3), 4.54 (2H, s, ArCH2N), 6.87 (IH, d, J 16.4Hz, CH=CHPh), 6.98 (IH, dt, ArH), 7.07 (IH, d, ArH), 7.33 (2H, m, ArH), 7.49 (3H, m, ArH), 7.58 (2H, m, ArH), 7.88 (IH, d, J 16.5Hz, CH=CHPh), 8.83 (IH, br s, NH), 9.42 (IH, br s, NH), 9.82 (IH, br s, NH); m/z (ES+) 281 ([M+H]+).
EXAMPLE 33
(E) -N- (2-Phenylbenzyl)cinnamamidine hydrochloride δH (360MHz, DMSO-de) 4.47 (2H, s, ArCH2N), 6.79 (IH, d, J 16.4Hz, CH=CHPh), 7.34-7.46 (12Η, m, ArH), 7.58 (2H, m, ArH), 7.77 (IH, d, J 16.4Hz, CH=CHPh), 8.80 (IH, br s, NH), 9.26 (IH, br s, NH), 9.83 (IH. br s, NH); m/z (ES+) 313 ([M+H]+).
EXAMPLE 34
(j5)-N-(2-Furylmethyl)cinnamamidine hydrochloride δH (360MHz, DMSO-de) 4.64 (2H, s, ArCH2N), 6.49 (IH, m, ArH), 6.55 (IH, m, ArH), 6.80 (IH, d, J 16.4Hz, CH=CHPh), 7.50 (2Η, m, ArH), 7.59 (2H, m, ArH), 7.73 (IH, m, ArH), 7.83 (IH, d, J 16.5Hz, CH=CHPh); m/z (ES+) 226 ([M+H]+).
EXAMPLE 35
(E)-N-(Cvclohexyl')cinnamamidine hydrochloride δH (360MHz, DMSO-de) 1.19 (IH, m, AlkH), 1.33 (4H, m, AlkH), 1.61 (IH, m, AlkH), 1.75 (2H, m, AlkH), 1.91 (2H, m, AlkH), 3.65 (IH, m, AlkH), 6.84 (IH, d, J 16.5Hz, CH=CHPh), 7.50 (3Η, m, ArH), 7.58 (2H, m,
ArH), 7.83 (IH, d, J 16.5Hz, CH=CHPh), 8.69 (IH, br s, NH), 9.21 (IH, br s, NH), 9.49 (IH, br s, NH); m/z (ES+) 229 ([M+H +).
EXAMPLE 36
( )-N-(3-Methyl-l-butyl)cinnamamidine hydrochloride δH (360MHz, MeOH-d ) 1.00 (6H, m, AlkH), 1.62 (IH, m, AlkH), 3.39 (2H, t, AlkH), 3.83 (2H, s, AlkH), 6.70 (IH, d, J 16.5Hz, CH=CHPh), 7.47 (2Η, m, ArH), 7.54 (IH, m, ArH), 7.62 (2H, m, ArH), 7.70 (2H, d, J 16.4Hz, CH=CHPh); m/z (ES+) 217 ([M+H]+).
EXAMPLE 37
( -2-(3-Phenyl-l-imino-2-propenyl)-l, 2.3.4- tetrahvdroisoquinoline δH (400MHz, DMSO-de, 333K) 3.01 (2H, m, AlkH), 3.70 (2H, br s,
AlkH), 4.75 (2H, br s, AlkH), 7.20 (IH, d, J 16.1Hz, CH=CHPh), 7.23-7.29 (4Η, m, ArH), 7.50 (3H, m, ArH), 7.62 (IH, d, J 16.1Hz, CH=CHPh), 7.76 (2H, m, ArH), 8.98 (3H, br s, 3 x NH); m/z (ES+) 263 ([M+H]+).
EXAMPLE 38
(j5D-N-(? -Pentyl)cinnamamidine hydrochloride δH (360MHz, DMSO-de) 0.90 (3H, t, J 7.1Hz, CH3), 1.33 (4H, m, AlkH), 1.61 (2H, m, AlkH), 6.85 (IH, d, J 16.5Hz, CH=CHPh), 7.49 (3Η, m, ArH), 7.59 (2H, m, ArH), 7.83 (IH, d, J 16.5Hz, CH=CHPh), 8.70 (IH, br s, NH), 9.30 (IH, br s, NH), 9.80 (IH, br s, NH); m/z (ES+) 217 (|M+H]+).
EXAMPLE 39
(jg)-N-(3-Phenyl-l-propyl)cinnamamidine hydrogen oxalate
δH (360MHz, DMSO-de) 1.92 (2H, m, AlkH), 2.69 (2H, m, AlkH), 3.33 (2H, m, AlkH), 6.79 (IH, d, J 16.4Hz, CH=CHPh), 7.26 (5Η, m, ArH), 7.50 (3H, m, ArH), 7.60 (2H, m, ArH), 7.76 (IH, d, J 16.6Hz, CH=CHPh), 8.65 (IH, br s, NH), 9.21 (IH, br s, NH), 9.67 (IH, br s, NH); m/z (ES+) 265 ([M+H]+).
EXAMPLE 40
(£)-N-(2-Hvdroxybenzyl)cinnamamidine 2-Hydroxybenzylamine (276.4mg, 2.24mmol) and sodium methoxide
(123.2mg, 2.28mmol) were added to a solution of (E)-ethyl cinnamimidate hydrochloride (482.3mg, 2.28mmol) [prepared by the method of E.G. Roberts and Y.F. Shealy, J. Het. Chem. 1974, 11, 54TI] in methanol (10ml) and the mixture stirred at room temperature for 6.5 hours. The reaction mixture was then poured into water (50ml) and extracted with dichloromethane (50ml then 2 x 25ml). The combined extracts were dried (MgSO4) and concentrated to a small volume. Methanol was added and the precipitate collected under suction, washed with methanol and dried in vacuo to give the title compound as a buff solid (90.2mg, 16%); 6H (360MHz, DMSO-de).4.25 (2H, s, ArCH2N), 6.61 (IH, d, J 16.5Hz,
CH=CHPh), 6.67 (2Η, m, ArH), 7.08 (2H, m, ArH), 7.31-7.43 (4H, m, ArH and CH=CHPh), 7.51 (2H, m, ArH); m/z (ES+) 253 (| +H]+).
EXAMPLE 41
( -N-Phenylcinnamamidine hydrochloride
Step 1: (B)-S-(2-Naphthylmethyl)thiocinnamimidate hydrobromide
2-Bromomethylnaphthalene (371.2mg, 1.68mmol) was added to a suspension of thiocinnamamide (273. lmg, 1.67mmol) [prepared by the method of I.T. Barnish, C.W.G. Fishwick, D.R. Hill and C. Szantay, Jr.,
Tetrahedron, 1989, 45, 6771] in chloroform (5ml). The mixture was heated
at reflux for 1.5 hours, allowed to cool and diluted with diethyl ether (5ml). The crystallised solid was collected under suction, washed with 50% chloroform in diethyl ether then diethyl ether and dried in vacuo to give the title compound as a pale yellow solid (436.6mg, 68%); δH (360MHz, CDCls) 5.11 (2H, s, ArCH2S), 7.41-7.55 (6H, m, ArH), 7.66 (2H, m, ArH), 7.76 (IH, d, J 16.2Hz, CH=CHPh), 7.83-7.88 (3Η, m, ArH), 7.96 (IH, d, J 16.2Hz, CH=CHPh), 8.02 (IH, s, ArH), 11.47 (IH, br s, NH), 12.28 (IH, br s, NH); m/z (ES+) 304 fl +H]+), 141 (100%).
Step 2: (E) -N-Phenylcinnamamidine hydrochloride
Aniline (51μl, 0.56mmol) was added to a solution of (E)-S-(2- naphthylmethyl)-thiocinnamimidate hydrobromide (216. lmg, 0.56mmol) in chloroform (4ml) and the mixture stirred at room temperature for 30 minutes. The reaction mixture was concentrated in vacuo, treated with saturated aqueous sodium hydrogen carbonate solution (20ml) and extracted with dichloromethane (2 x 10ml). The combined extracts were dried (MgSO4), concentrated and the residue purified by flash chromatography eluting with dichloromethane-methanol-ammonia (180:8:1). The purified product free base (50.2mg) was dissolved in dichloromethane and treated with 1M HC1 in diethyl ether (0.29ml). The mixture was evaporated and the residue recrystallised from methanol- diethyl ether to give the title compound (38.0mg, 26%); δH (360MHz, DMSO-de) 7.04 (IH, d, J 16.1Hz, CH=CHPh), 7.41-7.47 (3Η, m, ArH), 7.52- 7.59 (5H, m, ArH), 7.65 (2H, m, ArH), 8.06 (IH, d, J 16.1Hz, CH=CHPh), 8.72 (IH, br s, NH), 9.67 (IH, br s, NH), 11.73 (IH, br s, NH); m/z (ES+) 223 (PVM-H]+).
EXAMPLE 42
( -N-Benzyl-2-chlorocinnamamidine hydrochloride
- 32 -
Step 1: 2-(Diethylphosphono)-S-(2-naphthylmethyl)thioacetimidate hvdrobromide
2-Bromomethylnaphthalene (5.23g, 23.7mmol) was added to a solution of diethyl (2-amino-2-thioxoethyl)phosphonate (δ.OOg, 23.7mmol) in chloroform (50ml). The mixture was heated at reflux for 1.5 hours, allowed to cool and concentrated in vacuo. The residue was triturated with acetone and the resulting white solid collected under suction to give the title compound (7.84g, 77%); δH (360MHz, DMSO-de) 1.22 (6H, t, 7.0Hz, 2 x OCH2CH3) 3.81 (2Η, d, J 22Hz, CH2P), 4.09 (4H, m, 2 x OCH2CH3), 4.85 (2H, s, ArCH2S), 7.56 (3H, m, ArH), 7.89-7.98 (3H, m, ArH), 8.04 (IH, s, ArH); m/z (ES+) 352 ([M+H]+).
Step 2: N-Benzyl-2-(diethylphosphono)acetamidine hvdrobromide
Benzylamine (0.54ml, 4.95mmol) was added to a suspension of 2- (diethylphosphono)-S-(2-naphthylmethyl)thioacetimidatehydrobromide (2.1187g, 4.90mmol) in ethanol (10ml). The mixture was stirred at room temperature for 2 hours, then warmed and diluted with diethyl ether to cloud point. It was allowed to cool to give a crystalline solid, which was collected under suction, washed with 10% ethanol in diethyl ether then diethyl ether and dried in vacuo to afford the title compound (0.8520g,
48%); δH (360MHz, DMSO-de) 1.24 (6H, t, 7.0Hz, 2 x OCH2CH3) 3.22 (2Η, d, J 22Hz, CH2P), 4.09 (4H, m, 2 x OCH2CH3), 4.53 (2H, s, ArCH2N), 7.40 (5H, m, ArH), 9.04 (IH, v br s, NH), 9.24 (IH, v br s, NH), 9.94 (IH, v br s, NH); m/z (ES+) 285 ([M+HJ+).
Step 3: ( -N-Benzyl-2-chlorocinnamamidine hydrochloride
A rapidly stirred mixture of N-benzyl-2- (diethylphosphono)acetamidine hydrobromide (196.0mg, 0.537mmol), 2- chlorobenzaldehyde (63μl, 0.56mmol) and potassium carbonate (324.2mg, 2.35mmol) in tetrahydrofuran (10ml) was heated at reflux for 6 hours. The reaction mixture was poured into water (50ml) and extracted with
dichloromethane (2 x 25ml). The combined extracts were dried (MgSO4) and concentrated, then the residue was dissolved in methanol and treated with 1M HC1 in diethyl ether (0.6ml). The mixture was evaporated and the resulting solid recrystallised twice from methanol-diethyl ether to afford the title compound (57.5mg, 35%); δH (360MHz, DMSO-dβ) 4.65 (2H, br s, PhCH2N), 6.96 (IH, d, J 16.4Hz, CH=CHAr), 7.38 (IH, m, ArH), 7.43 (4H, m, ArH), 7.47-7.53 (2H, m, ArH), 7.59 (IH, m, ArH), 7.78 (IH, m, ArH), 8.09 (IH, d, J 16.4Hz, CH=CHAr), 9.10 (IH, br s, NH), 9.64 (IH, br s, NH), 10.36 (IH, br s, NH); m/z (ES+) 271/273 ([M+H]+).
The following Examples were prepared in an analogous process to the one described above:
EXAMPLE 43
(i?)-N-Benzyl-3-chlorocinnamamidine hydrochloride δH (360MHz, DMSO-de) 4.63 (2H, d, J 4.4Hz, PhCH2NH), 6.97 (IH, d, J 16.4Hz, CH=CHAr), 7.35-7.43 (5Η, m, ArH), 7.55 (3H, m, ArH), 7.65 (IH, s, ArH), 7.89 (IH, d, J 16.4Hz, CH=CHAr), 9.08 (IH, br s, NH), 9.55 (IH, br s, NH), 10.27 (IH, br s, NH); m/z (ES+) 271/273 (|M+H]+).
EXAMPLE 44
(.E)-N-Benzyl-4-chlorocinnamamidine hydrochloride δH (400MHz, DMSO-de) 4.61 (2H, d, J 5.8Hz, PhCH2NH), 6.86 (IH, d, J 16.4Hz, CH=CHAr), 7.33-7.45 (5Η, m, ArH), 7.56-7.63 (4H, m, ArH), 7.85 (IH, d, J 16.4Hz, CH=CHAr), 8.98 (IH, br s, NH), 9.44 (IH, br s, NH), 10.16 (IH, br s, NH); m/z (ES+) 271/273 ([M+H]+).
EXAMPLE 45
E)-N-Benzyl-4-fluorocinnamamidine hydrochloride δH (360MHz, DMSO-de) 4.61 (2H, d, J 5.9Hz, ArCH2N), 6.80 (IH, d, J 16.4Hz, CH=CHAr), 7.40 (7H, m, ArH), 7.67 (2H, m, ArH), 7.86 (IH, d, J 16.5Hz, CH=CHAr), 9.40 (1Η, br s, NΗ), 9.97 (1Η, br s, NΗ), 10.1 (1Η, br s, NΗ); m/z (ES+) 255 ([M+Η]+).
EXAMPLE 46
( -N-Benzyl-4-methoxycinnamamidine hydrochloride δH (360MHz, DMSO-de) 3.83 (3H, s, ArOCHs), 4.60 (2H, d, J 5.9Hz, ArCH2N), 6.69 (IH, d, J 16.3Hz, CH=CHAr), 7.06 (2H, d, J 8.8Hz, ArH), 7.41 (5H, m, ArH), 7.56 (2H, d, J 8.8Hz, ArH), 7.82 (IH, d, J 16.4Hz, CH=CHAr); m/z (ES+) 267 flM+Η]+).
EXAMPLE 47
f -N-Benzyl-3-methoxycinnamamidine hydrochloride δH (360MHz, DMSO-de) 3.81 (3H, s, ArOCHs), 4.61 (2H, s, ArCH2N),
6.88 (IH, d, J 16.5Hz, CH=CHAr), 7.41 (5H, , ArH), 7.07 (IH, m, ArH), 7.16 (2H, m, ArH), 7.40 (6H, m ArH), 7.83 (IH, d, J 16.4Hz, CH=CHAr); m/z (ES+) 267 ([M+Η]+).
EXAMPLE 48
( -N-Benzyl-2-methoxycinnamamidine hydrochloride δH (360MHz, DMSO-de) 3.90 (3H, s, ArOCHs), 4.60 (2H, d, J 5.9Hz, ArCH2N), 6.95 (IH, d, J 16.6Hz, CH=CHAr), 7.41 (5H, m, ArH), 7.06 (IH, t, J 7.4Hz, ArH), 7.16 (IH, d, J 8.3Hz, ArH), 7.45 (6H, ArH), 7.98 (IH, d,
J 16.6Hz, CH=CHAr), 9.9 (1Η, br s, NΗ), 9.40 (1Η, br s, NΗ), 10.10 (1Η, br s, NΗ); m/z (ES+) 267 ([M+Η]+).
EXAMPLE 49
(E) -N-Benzyl- 3 , 4-difluorocinnamamidine hydrochloride δH (360MHz, DMSO-de) 4.62 (2H, s, ArCH2N), 6.87 (IH, d, J 16.4Hz, CH=CHAr), 7.35-7.48 (6H, m, ArH), 7.57 (IH, m, ArH), 7.71 (IH, m, ArH), 7.82 (IH, d, J 16.4Hz, CH=CHAr), 9.03 (1Η, br s NΗ), 9.49 (1Η, br s, NΗ), 10.22 (1Η, br s, NΗ); m/z (ES+) 272 ([M+ΗJ+).
EXAMPLE 50
( -N-Benzyl-3-cvclohexaneacrylamidine hydrochloride δH (360MHz, DMSO-de) 1.07-1.35 (5H, m, AlkH), 1.62-1.74 (5H, m,
AlkH), 2.19-2.26 (IH, m, AlkH), 4.53 (2H, s, ArCH2N), 1.91 (2H, m, AlkH), 6.06 (IH, dd, J 16.2Hz, 1.1Hz, CH=CHc-Hex), 7.04 (IH, dd, J 16.2Hz, 6.6Hz, CH=CHc-Hex), 7.33-7.46 (5H, m, ArH), 9.00 (IH, br s, NH), 9.21 (IH, br s, NH), 10.00 (IH, br s, NH); m/z (ES+) 243 ([M+H]+).
Claims (11)
1. A compound of formula I, or a pharmaceutically acceptable salt, hydrate or prodrug thereof:
)
wherein:
R1 represents Ci-β alkyl, C3-7 cycloalkyl, C3-7 cycloalkyl(Cι-6)alkyl, aryl, aryl(Cι-6)alkyl or heteroaryl(Cι-6) alkyl, any of which groups may be optionally substituted;
R2 represents C3-7 cycloalkyl, aryl or heteroaryl, any of which groups may be optionally substituted; and
R3 represents hydrogen or Ci-β alkyl; or R1 and R3 are taken together with the intervening nitrogen atom to form an optionally substituted isoquinoline ring.
2. A compound as claimed in claim 1 represented by formula IIA, and pharmaceutically acceptable salts, hydrates or prodrugs thereof:
wherein R2 and R3 are as defined in claim 1;
R21 represents hydrogen, Ci-β alkyl, aryl, halogen, trihalo(Cι-e)alkyl, hydroxy, Ci-e alkoxy or trihalo(Cι-e) alkoxy; and R22 represents hydrogen or halogen.
3. A compound as claimed in claim 1 represented by formula IIB, and pharmaceutically acceptable salts, hydrates or prodrugs thereof:
wherein R1 and R3 are as defined in claim 1;
R31 represents hydrogen, Ci-β alkyl, halogen or Ci-β alkoxy; and R32 represents hydrogen or halogen.
4. A compound as claimed in any one of the preceding claims represented by formula IIC, and pharmaceutically acceptable salts, hydrates or prodrugs thereof:
wherein R3 is as defined in claim 1;
R21 and R22 are as defined in claim 2; and R31 and R32 are as defined in claim 3.
5. A compound as claimed in claim 4 represented by formula IID, and pharmaceutically acceptable salts, hydrates or prodrugs thereof:
wherein R3 is as defined in claim 1;
R21 and R22 are as defined in claim 2; and R31 is as defined in claim 3.
6. A compound selected from:
(i^-N-(3-iodobenzyl)cinnamamidine;
( )-N-(benzyl)cinnamamidine; (E) -N- (4-chlorobenzyl)cinnamamidine ;
(£ -N-(2-chlorobenzyl)cinnamamidine;
( )-N-(3-chlorobenzyl)cinnamamidine;
(S)-N-(4-fluorobenzyl)cinnamamidine;
(E)-N-(4-trifluoromethylbenzyl)cinnamamidine; (E) -N- (4-methoxybenzyl)cinnamamidine ;
(E)-N-(4-methylbenzyl)cinnamamidine;
(jB)-N-(3-methylbenzyl)cinnamamidine;
(Jδ )-N-(2-methylbenzyl)cinnamamidine;
(E) -N- (3 , 4- dichlorobenzyl)cinnamamidine ; (£ -N-(2-phenylethyl)cinnamamidine;
(£)-N-(J?)-α-methylbenzylcinnamamidine;
(E) -N- (S) -α-methylbenzylcinnamamidine ;
(£)-N-(3-trifluoromethylbenzyl)cinnamamidine;
(E)-N-(3, 5-dichlorobenzyl)cinnamamidine ; (JB)-N-(2-methoxybenzyl)cinnamamidine;
(EJ)-N-(3-methoxybenzyl)cinnamamidine;
(£ -N-(2-trifluoromethylbenzyl)cinnamamidine; (E)-N-(2,5-dichlorobenzyl)cinnamamidine;
(£ -N-(3-bromobenzyl)cinnamamidine;
(E)-N-(4-pyridylmethyl)cinnamamidine;
(£)-N-methyl-N-benzylcinnamamidine; (jE)-N-(2,3-dichlorobenzyl)cinnamamidine;
(£ -N-(cyclohexylmethyl)cinnamamidine;
(E) -N- (isobutyl)cinnamamidine ;
(E) -N- (τι-butyl)cinnamamidine ;
(£)-N-(2-trifluoromethoxybenzyl)cinnamamidine; (£ -N-(3-thienylmethyl)cinnamamidine;
(jB)-N-(2-bromobenzyl)cinnamamidine;
(JB)-N-(2-ethoxybenzyl)cinnamamidine;
(jE)-N-(2-phenylbenzyl)cinnamamidine;
(JE)-N-(2-furylmethyl)cinnamamidine; (E) -N- (cyclohexyl)cinnamamidine ;
(E)-N-(3-methyl-l-butyl)cinnamamidine;
(JS -2-(3-phenyl-l-imino-2-propenyl)-l,2,3,4-tetrahydroisoquinoline;
(E) -N- (τι-p entyl)cinnamamidine ;
(E)-N-(3-phenyl-l-propyl)cinnamamidine; (jB)-N-(2-hydroxybenzyl)cinnamamidine;
(i^-N-phenylcinnamamidine;
(£)-N-benzyl-2-chlorocinnamamidine;
( )-N-benzyl-3-chlorocinnamamidine;
(£ -N-benzyl-4-chlorocinnamamidine; (S)-N-benzyl-4-fluorocinnamamidine;
(£)-N-benzyl-4-methoxycinnamamidine;
(jE)-N-benzyl-3-methoxycinnamamidine;
(jE)-N-benzyl-2-methoxycinnamamidine;
( )-N-benzyl-3,4-difluorocinnamamidine; (E)-N-benzyl-3-cyclohexaneacrylamidine; and pharmaceutically acceptable salts, hydrates and prodrugs thereof.
7. A pharmaceutical composition comprising a compound of formula I as defined in claim 1 or a pharmaceutically acceptable salt, hydrate or prodrug thereof in combination with a pharmaceutically acceptable carrier.
8. A compound as claimed in any one of claims 1 to 6 for use in therapy.
9. The use of a compound as claimed in any one of claims 1 to 6 for the manufacture of a medicament for the treatment and/or prevention of neurological and neurodegenerative disorders.
10. A process for the preparation of a compound as claimed in claim 1 which comprises:
(A) reacting a compound of formula III with a compound of formula IV:
wherein R1, R2 and R3 are as defined in claim 1, and Rx represents Cι-6 alkyl; or
(B) reacting a compound of formula IV with a compound of formula VII:
(IV) (VII)
wherein R1, R2 and R3 are as defined in claim 1; or
(C) reacting a compound of formula XI with a compound of formula XII:
(XI) (XII)
wherein R1, R2 and R3 are as defined in claim 1; and (D) subsequently, if desired, converting a compound of formula I initially obtained into a further compound of formula I by standard methods.
11. A method for the treatment and/or prevention of neurological and neurodegenerative disorders which comprises administering to a patient in need of such treatment an effective amount of a compound of formula I as defined in claim 1, or a pharmaceutically acceptable salt, hydrate or prodrug thereof.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0015488.0A GB0015488D0 (en) | 2000-06-23 | 2000-06-23 | Therapeutic agents |
GB0015488.0 | 2000-06-23 | ||
PCT/GB2001/002621 WO2001098262A1 (en) | 2000-06-23 | 2001-06-14 | Amidine derivatives as selective antagonists of nmda receptors |
Publications (2)
Publication Number | Publication Date |
---|---|
AU2001264116A1 true AU2001264116A1 (en) | 2002-03-21 |
AU2001264116B2 AU2001264116B2 (en) | 2006-04-13 |
Family
ID=9894319
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU6411601A Pending AU6411601A (en) | 2000-06-23 | 2001-06-14 | Amidine derivatives as selective antagonists of nmda receptors |
AU2001264116A Ceased AU2001264116B2 (en) | 2000-06-23 | 2001-06-14 | Amidine derivatives as selective antagonists of NMDA receptors |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU6411601A Pending AU6411601A (en) | 2000-06-23 | 2001-06-14 | Amidine derivatives as selective antagonists of nmda receptors |
Country Status (8)
Country | Link |
---|---|
EP (1) | EP1296940B1 (en) |
JP (1) | JP2004501136A (en) |
AT (1) | ATE399762T1 (en) |
AU (2) | AU6411601A (en) |
CA (1) | CA2412164C (en) |
DE (1) | DE60134645D1 (en) |
GB (1) | GB0015488D0 (en) |
WO (1) | WO2001098262A1 (en) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7732162B2 (en) | 2003-05-05 | 2010-06-08 | Probiodrug Ag | Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases |
US7423149B2 (en) * | 2003-12-23 | 2008-09-09 | Schering Corporation | Substituted n-aryl amidines as selective D1 dopamine receptor antagonists for the treatment of obesity and CNS disorders |
HUP0401523A3 (en) * | 2004-07-29 | 2007-05-02 | Richter Gedeon Vegyeszet | Indole-2-carboxamide derivatives, pharmaceutical compositions containing them and process for producing them |
KR20080035294A (en) * | 2006-10-19 | 2008-04-23 | 한국과학기술연구원 | Pharmaceutical composition for prevention and treatment of parkinson's disease containing 1,2-di[2-methoxy-4-(2-carboxylvinyl)]phenoxyethane as an active ingredient |
EP2089383B1 (en) | 2006-11-09 | 2015-09-16 | Probiodrug AG | 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases |
ATE554085T1 (en) | 2006-11-30 | 2012-05-15 | Probiodrug Ag | NEW INHIBITORS OF GLUTAMINYL CYCLASE |
MX2009009234A (en) | 2007-03-01 | 2009-12-01 | Probiodrug Ag | New use of glutaminyl cyclase inhibitors. |
WO2008128985A1 (en) | 2007-04-18 | 2008-10-30 | Probiodrug Ag | Thiourea derivatives as glutaminyl cyclase inhibitors |
KR101755737B1 (en) | 2009-09-11 | 2017-07-07 | 프로비오드룩 아게 | Heterocyclic derivatives as inhibitors of glutaminyl cyclase |
US9181233B2 (en) | 2010-03-03 | 2015-11-10 | Probiodrug Ag | Inhibitors of glutaminyl cyclase |
CA2789440C (en) | 2010-03-10 | 2020-03-24 | Probiodrug Ag | Heterocyclic inhibitors of glutaminyl cyclase (qc, ec 2.3.2.5) |
JP5945532B2 (en) | 2010-04-21 | 2016-07-05 | プロビオドルグ エージー | Benzimidazole derivatives as inhibitors of glutaminyl cyclase |
ES2570167T3 (en) | 2011-03-16 | 2016-05-17 | Probiodrug Ag | Benzimidazole derivatives as glutaminyl cyclase inhibitors |
EP2838530B1 (en) | 2012-04-20 | 2017-04-05 | UCB Biopharma SPRL | Methods for treating parkinson's disease |
CN106905273B (en) * | 2017-01-18 | 2019-05-14 | 中山大学 | 4- oxa- -4,5,6,7- tetrahydro benzo [B] furans -3- carboxylic acid compound and its application |
ES2812698T3 (en) | 2017-09-29 | 2021-03-18 | Probiodrug Ag | Glutaminyl cyclase inhibitors |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3476768A (en) * | 1965-05-17 | 1969-11-04 | Pfizer & Co C | Thienylalanine |
IL26870A (en) * | 1965-12-30 | 1971-01-28 | Pfizer | Imidazoline and tetrahydropyrimidine derivatives,their preparation and use |
JPH10287637A (en) * | 1997-04-14 | 1998-10-27 | Banyu Pharmaceut Co Ltd | Amidine derivative |
-
2000
- 2000-06-23 GB GBGB0015488.0A patent/GB0015488D0/en not_active Ceased
-
2001
- 2001-06-14 WO PCT/GB2001/002621 patent/WO2001098262A1/en active IP Right Grant
- 2001-06-14 AU AU6411601A patent/AU6411601A/en active Pending
- 2001-06-14 AU AU2001264116A patent/AU2001264116B2/en not_active Ceased
- 2001-06-14 AT AT01938439T patent/ATE399762T1/en not_active IP Right Cessation
- 2001-06-14 DE DE60134645T patent/DE60134645D1/en not_active Expired - Lifetime
- 2001-06-14 CA CA2412164A patent/CA2412164C/en not_active Expired - Fee Related
- 2001-06-14 EP EP01938439A patent/EP1296940B1/en not_active Expired - Lifetime
- 2001-06-14 JP JP2002504218A patent/JP2004501136A/en not_active Withdrawn
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2412164C (en) | Amidine derivatives as selective antagonists of nmda receptors | |
JP5975025B2 (en) | Imidazopyridine compounds | |
EP2927231B1 (en) | Imidazopyridine compounds | |
AU2001264116A1 (en) | Amidine derivatives as selective antagonists of NMDA receptors | |
US12006328B2 (en) | Thieno[2,3-d]pyrimidin-4-one derivatives as NMDAR modulators and uses related thereto | |
AU757290B2 (en) | Imidazolone anorectic agents: II. phenyl derivatives | |
EP0858996B1 (en) | Nerve cell protective agents | |
US20090227571A1 (en) | Androgen Receptor Modulator Compounds and Methods | |
JP4685243B2 (en) | Pyrimido [6,1-a] isoquinolin-4-one derivatives | |
SK822002A3 (en) | New compounds | |
FI78691C (en) | Process for the preparation of position 3-substituted pyridazine derivatives which affect the central nervous system | |
US20060014951A1 (en) | 4-amino-substituted pyrimidine derivatives | |
JP2016169161A (en) | Novel imidazo pyridine compound | |
TW201100425A (en) | Oxidated derivatives of triazolylpurines useful as ligands of the adenosine A2A receptor and their use as medicaments | |
JP2000501432A (en) | New indole-2,3-dione-3-oxime derivatives | |
CA2454785C (en) | 4-oxoimidazolidine-2-spiropiperidine derivatives | |
KR20010006951A (en) | Novel thiazolobenzoimidazole derivatives | |
WO2008024151A2 (en) | Salts and co-crystals of pyrazolopyrimidine compounds, compositions thereof and methods for their production and use | |
JP2019501949A (en) | Adenosine A3 receptor antagonist compound, preparation method thereof, and medical use thereof | |
KR20200035077A (en) | New propanamine derivatives for the treatment of pain and pain-related conditions | |
JP6936257B2 (en) | Pyrazole compound as an EAAT3 inhibitor | |
KR910002566B1 (en) | 2.3.4.5.6.7-hexahydro-2.7-methano-1.5-benzoxazonine compounds its preparation method and pharmaceutical composition containing htereof | |
WO2008080290A1 (en) | Selective m4 receptor antagonist and its medical use | |
US20230322735A1 (en) | Azetidinyl tryptamines and methods of treating psychiatric disorders | |
US20030119871A1 (en) | Amidine derivatives as selective antagonists of ndma receptors |